| Year |
Citation |
Score |
| 2024 |
Bosch ME, Dodiya HB, Michalkiewicz J, Lee C, Shaik SM, Weigle IQ, Zhang C, Osborn J, Nambiar A, Patel P, Parhizkar S, Zhang X, Laury ML, Mondal P, Gomm A, ... ... Holtzman DM, et al. Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner. Molecular Neurodegeneration. 19: 70. PMID 39390529 DOI: 10.1186/s13024-024-00764-2 |
0.742 |
|
| 2024 |
Capocchi JK, Figueroa-Romero C, Dunham SJB, Faraci G, Rothman JA, Whiteson KL, Seo DO, Holtzman DM, Grabrucker S, Nolan YM, Kaddurah-Daouk R, Jett DA. Symposium: What Does the Microbiome Tell Us about Prevention and Treatment of AD/ADRD? The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 44. PMID 39384409 DOI: 10.1523/JNEUROSCI.1295-24.2024 |
0.394 |
|
| 2024 |
Carling GK, Fan L, Foxe NR, Norman K, Wong MY, Zhu D, Corona C, Razzoli A, Yu F, Yarahmady A, Ye P, Chen H, Huang Y, Amin S, Sereda R, ... ... Holtzman DM, et al. Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model. Neuron. PMID 39353433 DOI: 10.1016/j.neuron.2024.09.006 |
0.379 |
|
| 2024 |
Chen Y, Holtzman DM. New insights into innate immunity in Alzheimer's disease: from APOE protective variants to therapies. Trends in Immunology. PMID 39278789 DOI: 10.1016/j.it.2024.08.001 |
0.354 |
|
| 2024 |
Walia A, Shew MA, Durakovic N, Herzog JA, Cirrito JR, Yuede CM, Wick CC, Manis M, Holtzman DM, Buchman CA, Rutherford MA. Alzheimer's Disease-Related Analytes Amyloid-β and Tau in Perilymph: Correlation With Patient Age and Cognitive Score. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. PMID 39189154 DOI: 10.1002/ohn.942 |
0.65 |
|
| 2024 |
Coulton JB, He Y, Barthélemy NR, Jiang H, Holtzman DM, Bateman RJ. Multi-peptide characterization of plasma neurofilament light chain in preclinical and mild Alzheimer's disease. Brain Communications. 6: fcae247. PMID 39165480 DOI: 10.1093/braincomms/fcae247 |
0.447 |
|
| 2024 |
Sun Z, Kwon JS, Ren Y, Chen S, Walker CK, Lu X, Cates K, Karahan H, Sviben S, Fitzpatrick JAJ, Valdez C, Houlden H, Karch CM, Bateman RJ, Sato C, ... ... Holtzman DM, et al. Modeling late-onset Alzheimer's disease neuropathology via direct neuronal reprogramming. Science (New York, N.Y.). 385: adl2992. PMID 39088624 DOI: 10.1126/science.adl2992 |
0.686 |
|
| 2024 |
Janelidze S, Barthélemy NR, Salvadó G, Schindler SE, Palmqvist S, Mattsson-Carlgren N, Braunstein JB, Ovod V, Bollinger JG, He Y, Li Y, Raji CA, Morris JC, Holtzman DM, Ashton NJ, et al. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment. Jama Neurology. PMID 39068669 DOI: 10.1001/jamaneurol.2024.2619 |
0.563 |
|
| 2024 |
Nath A, Holtzman DM, Miller BL, Grinberg LT, Leschek EW. Insufficient evidence for an association between iatrogenic Alzheimer's disease and cadaveric pituitary-derived growth hormone. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 39034810 DOI: 10.1002/alz.14127 |
0.352 |
|
| 2024 |
Kloske CM, Belloy ME, Blue EE, Bowman GR, Carrillo MC, Chen X, Chiba-Falek O, Davis AA, Paolo GD, Garretti F, Gate D, Golden LR, Heinecke JW, Herz J, Huang Y, ... ... Holtzman DM, et al. Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 39031528 DOI: 10.1002/alz.13877 |
0.593 |
|
| 2024 |
Fernandez MV, Liu M, Beric A, Johnson M, Cetin A, Patel M, Budde J, Kohlfeld P, Bergmann K, Lowery J, Flynn A, Brock W, Sanchez Montejo B, Gentsch J, Sykora N, ... ... Holtzman DM, et al. Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research Center. Scientific Data. 11: 768. PMID 38997326 DOI: 10.1038/s41597-024-03485-9 |
0.676 |
|
| 2024 |
Brier MR, Schindler SE, Salter A, Perantie D, Shelley N, Judge B, Keefe S, Kirmess KM, Verghese PB, Yarasheski KE, Venkatesh V, Raji CA, Gordon BA, Bateman RJ, Morris JC, ... ... Holtzman DM, et al. Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients. Annals of Neurology. PMID 38963256 DOI: 10.1002/ana.27027 |
0.738 |
|
| 2024 |
Xiong C, Luo J, Wolk DA, Shaw LM, Roberson ED, Murchison CF, Henson RL, Benzinger TLS, Bui Q, Agboola F, Grant E, Gremminger EN, Moulder KL, Geldmacher DS, Clay OJ, ... ... Holtzman DM, et al. Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals. Nature Communications. 15: 5539. PMID 38956096 DOI: 10.1038/s41467-024-49859-w |
0.537 |
|
| 2024 |
Ibanez L, Liu M, Beric A, Timsina J, Kholfeld P, Bergmann K, Lowery J, Sykora N, Sanchez-Montejo B, Brock W, Budde JP, Bateman RJ, Barthelemy N, Schindler SE, Holtzman DM, et al. Benchmarking of a multi-biomarker low-volume panel for Alzheimer's Disease and related dementia research. Medrxiv : the Preprint Server For Health Sciences. PMID 38947090 DOI: 10.1101/2024.06.13.24308895 |
0.513 |
|
| 2024 |
Narasimhan S, Holtzman DM, Apostolova LG, Cruchaga C, Masters CL, Hardy J, Villemagne VL, Bell J, Cho M, Hampel H. Apolipoprotein E in Alzheimer's disease trajectories and the next-generation clinical care pathway. Nature Neuroscience. PMID 38898183 DOI: 10.1038/s41593-024-01669-5 |
0.356 |
|
| 2024 |
Xia Z, Prescott EE, Urbanek A, Wareing HE, King MC, Olerinyova A, Dakin H, Leah T, Barnes KA, Matuszyk MM, Dimou E, Hidari E, Zhang YP, Lam JYL, Danial JSH, ... ... Holtzman DM, et al. Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer's disease. Nature Communications. 15: 4695. PMID 38824138 DOI: 10.1038/s41467-024-49028-z |
0.424 |
|
| 2024 |
Litvinchuk A, Suh JH, Guo JL, Lin K, Davis SS, Bien-Ly N, Tycksen E, Tabor GT, Serrano JR, Manis M, Bao X, Lee C, Bosch M, Perez EJ, Yuede CM, ... ... Holtzman DM, et al. Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist. Neuron. PMID 38823392 DOI: 10.1016/j.neuron.2024.05.021 |
0.788 |
|
| 2024 |
Shue F, White LJ, Hendrix R, Ulrich J, Henson RL, Knight W, Martens YA, Wang N, Roy B, Starling SC, Ren Y, Xiong C, Asmann YW, Syrjanen JA, Vassilaki M, ... ... Holtzman DM, et al. CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly. Science Advances. 10: eadk3674. PMID 38569027 DOI: 10.1126/sciadv.adk3674 |
0.823 |
|
| 2024 |
Hou J, Chen Y, Cai Z, Heo GS, Yuede CM, Wang Z, Lin K, Saadi F, Trsan T, Nguyen AT, Constantopoulos E, Larsen RA, Zhu Y, Wagner ND, McLaughlin N, ... ... Holtzman DM, et al. Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model. Science Translational Medicine. 16: eadj9052. PMID 38569016 DOI: 10.1126/scitranslmed.adj9052 |
0.375 |
|
| 2024 |
Canestaro WJ, Bateman RJ, Holtzman DM, Monane M, Braunstein JB. Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment. Population Health Management. PMID 38546435 DOI: 10.1089/pop.2023.0309 |
0.479 |
|
| 2024 |
Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV. Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Molecular Neurodegeneration. 19: 27. PMID 38519970 DOI: 10.1186/s13024-024-00716-w |
0.706 |
|
| 2024 |
Salvadó G, Horie K, Barthélemy NR, Vogel JW, Pichet Binette A, Chen CD, Aschenbrenner AJ, Gordon BA, Benzinger TLS, Holtzman DM, Morris JC, Palmqvist S, Stomrud E, Janelidze S, Ossenkoppele R, et al. Disease staging of Alzheimer's disease using a CSF-based biomarker model. Nature Aging. PMID 38514824 DOI: 10.1038/s43587-024-00599-y |
0.547 |
|
| 2024 |
Meeker KL, Luckett PH, Barthélemy NR, Hobbs DA, Chen C, Bollinger J, Ovod V, Flores S, Keefe S, Henson RL, Herries EM, McDade E, Hassenstab JJ, Xiong C, Cruchaga C, ... ... Holtzman DM, et al. Comparison of cerebrospinal fluid, plasma and neuroimaging biomarker utility in Alzheimer's disease. Brain Communications. 6: fcae081. PMID 38505230 DOI: 10.1093/braincomms/fcae081 |
0.553 |
|
| 2024 |
Jackson RJ, Keiser MS, Meltzer JC, Fykstra DP, Dierksmeier SE, Hajizadeh S, Kreuzer J, Morris R, Melloni A, Nakajima T, Tecedor L, Ranum PT, Carrell E, Chen Y, Nishtar MA, ... Holtzman DM, et al. APOE2 gene therapy reduces amyloid deposition, and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 38504517 DOI: 10.1016/j.ymthe.2024.03.024 |
0.434 |
|
| 2024 |
Meyer MR, Kirmess KM, Eastwood S, Wente-Roth TL, Irvin F, Holubasch MS, Venkatesh V, Fogelman I, Monane M, Hanna L, Rabinovici GD, Siegel BA, Whitmer RA, Apgar C, Bateman RJ, ... Holtzman DM, et al. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 38491912 DOI: 10.1002/alz.13764 |
0.832 |
|
| 2024 |
Toral-Rios D, Long JM, Ulrich JD, Yu J, Strickland MR, Han X, Holtzman DM, Cashikar AG, Paul SM. Cholesterol 25-hydroxylase mediates neuroinflammation and neurodegeneration in a mouse model of tauopathy. The Journal of Experimental Medicine. 221. PMID 38442267 DOI: 10.1084/jem.20232000 |
0.439 |
|
| 2024 |
Li Y, Yen D, Hendrix RD, Gordon BA, Dlamini S, Barthélemy NR, Aschenbrenner AJ, Henson RL, Herries EM, Volluz K, Kirmess K, Eastwood S, Meyer M, Heller M, Jarrett L, ... ... Holtzman DM, et al. Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset. Annals of Neurology. PMID 38400792 DOI: 10.1002/ana.26891 |
0.817 |
|
| 2024 |
Bosch ME, Dodiya HB, Michalkiewicz J, Lee C, Shaik SM, Weigle IQ, Zhang C, Osborn J, Nambiar A, Patel P, Parhizkar S, Zhang X, Laury ML, Mondal P, Gomm A, ... ... Holtzman DM, et al. Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner. Molecular Neurodegeneration. 19: 18. PMID 38365827 DOI: 10.1186/s13024-023-00700-w |
0.82 |
|
| 2024 |
Carling GK, Fan L, Foxe NR, Norman K, Ye P, Wong MY, Zhu D, Yu F, Xu J, Yarahmady A, Chen H, Huang Y, Amin S, Zacharioudakis E, Chen X, ... Holtzman DM, et al. Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model. Biorxiv : the Preprint Server For Biology. PMID 38328219 DOI: 10.1101/2024.01.24.577107 |
0.564 |
|
| 2024 |
Cadiz MP, Gibson KA, Todd KT, Nascari DG, Massa N, Lilley MT, Olney KC, Al-Amin MM, Jiang H, Holtzman DM, Fryer JD. Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. The Journal of Experimental Medicine. 221. PMID 38226975 DOI: 10.1084/jem.20231363 |
0.385 |
|
| 2024 |
Vance JM, Farrer LA, Huang Y, Cruchaga C, Hyman BT, Pericak-Vance MA, Goate AM, Greicius MD, Griswold AJ, Haines JL, Tcw J, Schellenberg GD, Tsai LH, Herz J, Holtzman DM. Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease. Annals of Neurology. PMID 38180638 DOI: 10.1002/ana.26864 |
0.362 |
|
| 2024 |
Seo DO, Holtzman DM. Current understanding of the Alzheimer's disease-associated microbiome and therapeutic strategies. Experimental & Molecular Medicine. PMID 38172602 DOI: 10.1038/s12276-023-01146-2 |
0.377 |
|
| 2023 |
Chen Y, Song S, Parhizkar S, Lord J, Zhu Y, Strickland MR, Wang C, Park J, Tabor GT, Jiang H, Li K, Davis AA, Yuede CM, Colonna M, Ulrich JD, ... Holtzman DM, et al. APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread. Cell. PMID 38086389 DOI: 10.1016/j.cell.2023.11.029 |
0.435 |
|
| 2023 |
Litvinchuk A, Suh JH, Guo JL, Lin K, Davis SS, Bien-Ly N, Tycksen E, Tabor GT, Remolina Serrano J, Manis M, Bao X, Lee C, Bosch M, Perez EJ, Yuede CM, ... ... Holtzman DM, et al. Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist. Neuron. PMID 37995685 DOI: 10.1016/j.neuron.2023.10.023 |
0.814 |
|
| 2023 |
Tabor GT, Holtzman DM. Current status of amyloid-targeting immunotherapies for Alzheimer's disease. Science Translational Medicine. 15: eadk9993. PMID 37939161 DOI: 10.1126/scitranslmed.adk9993 |
0.318 |
|
| 2023 |
Yin Z, Rosenzweig N, Kleemann KL, Zhang X, Brandão W, Margeta MA, Schroeder C, Sivanathan KN, Silveira S, Gauthier C, Mallah D, Pitts KM, Durao A, Herron S, Shorey H, ... ... Holtzman DM, et al. APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints. Nature Immunology. PMID 37749326 DOI: 10.1038/s41590-023-01627-6 |
0.444 |
|
| 2023 |
Lau SF, Wu W, Wong HY, Ouyang L, Qiao Y, Xu J, Lau JH, Wong C, Jiang Y, Holtzman DM, Fu AKY, Ip NY. The VCAM1-ApoE pathway directs microglial chemotaxis and alleviates Alzheimer's disease pathology. Nature Aging. PMID 37735240 DOI: 10.1038/s43587-023-00491-1 |
0.423 |
|
| 2023 |
Self WK, Holtzman DM. Emerging diagnostics and therapeutics for Alzheimer disease. Nature Medicine. 29: 2187-2199. PMID 37667136 DOI: 10.1038/s41591-023-02505-2 |
0.385 |
|
| 2023 |
Jackson RJ, Keiser MS, Meltzer JC, Fykstra DP, Dierksmeier SE, Melloni A, Nakajima T, Tecedor L, Ranum PT, Carrell E, Chen Y, Holtzman DM, Davidson BL, Hyman BT. APOE2 gene therapy reduces amyloid deposition, and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease. Biorxiv : the Preprint Server For Biology. PMID 37645718 DOI: 10.1101/2023.08.14.552850 |
0.435 |
|
| 2023 |
Drieu A, Du S, Kipnis M, Bosch ME, Herz J, Lee C, Jiang H, Manis M, Ulrich JD, Kipnis J, Holtzman DM, Gratuze M. Parenchymal border macrophages regulate tau pathology and tau-mediated neurodegeneration. Life Science Alliance. 6. PMID 37562846 DOI: 10.26508/lsa.202302087 |
0.848 |
|
| 2023 |
Salvadó G, Horie K, Barthélemy NR, Vogel JW, Binette AP, Chen CD, Aschenbrenner AJ, Gordon BA, Benzinger TLS, Holtzman DM, Morris JC, Palmqvist S, Stomrud E, Janelidze S, Ossenkoppele R, et al. Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's disease. Medrxiv : the Preprint Server For Health Sciences. PMID 37503281 DOI: 10.1101/2023.07.14.23292650 |
0.58 |
|
| 2023 |
Horie K, Salvadó G, Barthélemy NR, Janelidze S, Li Y, He Y, Saef B, Chen CD, Jiang H, Strandberg O, Pichet Binette A, Palmqvist S, Sato C, Sachdev P, Koyama A, ... ... Holtzman DM, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease. Nature Medicine. PMID 37443334 DOI: 10.1038/s41591-023-02443-z |
0.692 |
|
| 2023 |
Ferreiro AL, Choi J, Ryou J, Newcomer EP, Thompson R, Bollinger RM, Hall-Moore C, Ndao IM, Sax L, Benzinger TLS, Stark SL, Holtzman DM, Fagan AM, Schindler SE, Cruchaga C, et al. Gut microbiome composition may be an indicator of preclinical Alzheimer's disease. Science Translational Medicine. 15: eabo2984. PMID 37315112 DOI: 10.1126/scitranslmed.abo2984 |
0.379 |
|
| 2023 |
Sun Z, Kwon JS, Ren Y, Chen S, Cates K, Lu X, Walker CK, Karahan H, Sviben S, Fitzpatrick JAJ, Valdez C, Houlden H, Karch CM, Bateman RJ, Sato C, ... ... Holtzman DM, et al. Endogenous recapitulation of Alzheimer's disease neuropathology through human 3D direct neuronal reprogramming. Biorxiv : the Preprint Server For Biology. PMID 37292658 DOI: 10.1101/2023.05.24.542155 |
0.763 |
|
| 2023 |
Wang C, Nambiar A, Strickland MR, Lee C, Parhizkar S, Moore AC, Musiek ES, Ulrich JD, Holtzman DM. APOE-ε4 synergizes with sleep disruption to accelerate Aβ deposition and Aβ-associated tau seeding and spreading. The Journal of Clinical Investigation. PMID 37279069 DOI: 10.1172/JCI169131 |
0.413 |
|
| 2023 |
Grizzanti J, Moritz WR, Pait MC, Stanley M, Kaye SD, Carroll CM, Constantino NJ, Deitelzweig LJ, Snipes JA, Kellar D, Caesar EE, Pettit-Mee RJ, Day SM, Sens JP, Nicol NI, ... ... Holtzman DM, et al. KATP channels are necessary for glucose dependent increases in amyloid-beta and Alzheimer's-related pathology. Jci Insight. PMID 37129980 DOI: 10.1172/jci.insight.162454 |
0.348 |
|
| 2023 |
Parhizkar S, Gent G, Chen Y, Rensing N, Gratuze M, Strout G, Sviben S, Tycksen E, Zhang Q, Gilmore PE, Sprung R, Malone J, Chen W, Remolina Serrano J, Bao X, ... ... Holtzman DM, et al. Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a -dependent manner in mice. Science Translational Medicine. 15: eade6285. PMID 37099634 DOI: 10.1126/scitranslmed.ade6285 |
0.744 |
|
| 2023 |
Lawler PE, Bollinger JG, Schindler SE, Hodge CR, Iglesias NJ, Krishnan V, Coulton JB, Li Y, Holtzman DM, Bateman RJ. Apolipoprotein E O-glycosylation is associated with amyloid plaques and APOE genotype. Analytical Biochemistry. 672: 115156. PMID 37072097 DOI: 10.1016/j.ab.2023.115156 |
0.561 |
|
| 2023 |
Fogelman I, West T, Braunstein JB, Verghese PB, Kirmess KM, Meyer MR, Contois JH, Shobin E, Ferber KL, Gagnon J, Rubel CE, Graham D, Bateman RJ, Holtzman DM, Huang S, et al. Independent study demonstrates amyloid probability score accurately indicates amyloid pathology. Annals of Clinical and Translational Neurology. PMID 36975407 DOI: 10.1002/acn3.51763 |
0.834 |
|
| 2023 |
Xiong M, Wang C, Gratuze M, Saadi F, Bao X, Bosch ME, Lee C, Jiang H, Serrano JR, Gonzales ER, Kipnis M, Holtzman DM. Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy. Molecular Neurodegeneration. 18: 17. PMID 36922879 DOI: 10.1186/s13024-023-00610-x |
0.854 |
|
| 2023 |
Musiek ES, McDade E, Holtzman DM. Lecanamab Ushers in a New Era of Anti-Amyloid Therapy for Alzheimer's Disease. Annals of Neurology. PMID 36919987 DOI: 10.1002/ana.26643 |
0.319 |
|
| 2023 |
Chen X, Firulyova M, Manis M, Herz J, Smirnov I, Aladyeva E, Wang C, Bao X, Finn MB, Hu H, Shchukina I, Kim MW, Yuede CM, Kipnis J, Artyomov MN, ... ... Holtzman DM, et al. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature. PMID 36890231 DOI: 10.1038/s41586-023-05788-0 |
0.59 |
|
| 2023 |
Caesar I, Nilsson KPR, Hammarstrom P, Lindgren M, Prokop S, Heppner FL, Schmeidler J, Haroutunian V, Holtzman DM, Hof PR, Gandy S. ApoE Alzheimer's Disease Aβ-amyloid plaque morphology varies according to APOE isotype. Research Square. PMID 36798327 DOI: 10.21203/rs.3.rs-2524641/v1 |
0.442 |
|
| 2023 |
Seo DO, O'Donnell D, Jain N, Ulrich JD, Herz J, Li Y, Lemieux M, Cheng J, Hu H, Serrano JR, Bao X, Franke E, Karlsson M, Meier M, Deng S, ... ... Holtzman DM, et al. ApoE isoform- and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy. Science (New York, N.Y.). 379: eadd1236. PMID 36634180 DOI: 10.1126/science.add1236 |
0.389 |
|
| 2022 |
Wisch JK, Butt OH, Gordon BA, Schindler SE, Fagan AM, Henson RL, Yang C, Boerwinkle AH, Benzinger TLS, Holtzman DM, Morris JC, Cruchaga C, Ances BM. Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression. Brain : a Journal of Neurology. PMID 36542469 DOI: 10.1093/brain/awac484 |
0.407 |
|
| 2022 |
Dincer A, Chen CD, McKay NS, Koenig LN, McCullough A, Flores S, Keefe SJ, Schultz SA, Feldman RL, Joseph-Mathurin N, Hornbeck RC, Cruchaga C, Schindler SE, Holtzman DM, Morris JC, et al. APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression. Science Translational Medicine. 14: eabl7646. PMID 36383681 DOI: 10.1126/scitranslmed.abl7646 |
0.305 |
|
| 2022 |
Gratuze M, Schlachetzki JCM, D'Oliveira Albanus R, Jain N, Novotny B, Brase L, Rodriguez L, Mansel C, Kipnis M, O'Brien S, Pasillas MP, Lee C, Manis M, Colonna M, Harari O, ... ... Holtzman DM, et al. TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4. Neuron. PMID 36368315 DOI: 10.1016/j.neuron.2022.10.022 |
0.793 |
|
| 2022 |
Chen X, Holtzman DM. Emerging roles of innate and adaptive immunity in Alzheimer's disease. Immunity. PMID 36351425 DOI: 10.1016/j.immuni.2022.10.016 |
0.54 |
|
| 2022 |
Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV. Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Molecular Neurodegeneration. 17: 71. PMID 36329501 DOI: 10.1186/s13024-022-00573-5 |
0.706 |
|
| 2022 |
Wang S, Sudan R, Peng V, Zhou Y, Du S, Yuede CM, Lei T, Hou J, Cai Z, Cella M, Nguyen K, Poliani PL, Beatty WL, Chen Y, Cao S, ... ... Holtzman DM, et al. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Cell. 185: 4153-4169.e19. PMID 36306735 DOI: 10.1016/j.cell.2022.09.033 |
0.408 |
|
| 2022 |
Jain N, Lewis CA, Ulrich JD, Holtzman DM. Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading. The Journal of Experimental Medicine. 220. PMID 36219197 DOI: 10.1084/jem.20220654 |
0.436 |
|
| 2022 |
Chen K, Martens YA, Meneses A, Ryu DH, Lu W, Raulin AC, Li F, Zhao J, Chen Y, Jin Y, Linares C, Goodwin M, Li Y, Liu CC, Kanekiyo T, ... Holtzman DM, et al. LRP1 is a neuronal receptor for α-synuclein uptake and spread. Molecular Neurodegeneration. 17: 57. PMID 36056345 DOI: 10.1186/s13024-022-00560-w |
0.47 |
|
| 2022 |
Wander CM, Tsujimoto THM, Ervin JF, Wang C, Maranto SM, Bhat V, Dallmeier JD, Wang SJ, Lin FC, Scott WK, Holtzman DM, Cohen TJ. Corpora amylacea are associated with tau burden and cognitive status in Alzheimer's disease. Acta Neuropathologica Communications. 10: 110. PMID 35941704 DOI: 10.1186/s40478-022-01409-5 |
0.314 |
|
| 2022 |
Schindler SE, Li Y, Li M, Despotis A, Park E, Vittert L, Hamilton BH, Womack KB, Saef B, Holtzman DM, Morris JC, Bateman RJ, Gupta MR. Using Alzheimer's disease blood tests to accelerate clinical trial enrollment. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35934777 DOI: 10.1002/alz.12754 |
0.51 |
|
| 2022 |
Long JM, Coble DW, Xiong C, Schindler SE, Perrin RJ, Gordon BA, Benzinger TLS, Grant E, Fagan AM, Harari O, Cruchaga C, Holtzman DM, Morris JC. Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes. Brain : a Journal of Neurology. PMID 35867858 DOI: 10.1093/brain/awac250 |
0.624 |
|
| 2022 |
Tcw J, Qian L, Pipalia NH, Chao MJ, Liang SA, Shi Y, Jain BR, Bertelsen SE, Kapoor M, Marcora E, Sikora E, Andrews EJ, Martini AC, Karch CM, Head E, ... Holtzman DM, et al. Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Cell. 185: 2213-2233.e25. PMID 35750033 DOI: 10.1016/j.cell.2022.05.017 |
0.319 |
|
| 2022 |
Capano LS, Sato C, Ficulle E, Yu A, Horie K, Kwon JS, Burbach KF, Barthélemy NR, Fox SG, Karch CM, Bateman RJ, Houlden H, Morimoto RI, Holtzman DM, Duff KE, et al. Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neurons. Cell Stem Cell. 29: 918-932.e8. PMID 35659876 DOI: 10.1016/j.stem.2022.04.018 |
0.625 |
|
| 2022 |
Hu Y, Kirmess KM, Meyer MR, Rabinovici GD, Gatsonis C, Siegel BA, Whitmer RA, Apgar C, Hanna L, Kanekiyo M, Kaplow J, Koyama A, Verbel D, Holubasch MS, Knapik SS, ... ... Holtzman DM, et al. Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. Jama Network Open. 5: e228392. PMID 35446396 DOI: 10.1001/jamanetworkopen.2022.8392 |
0.818 |
|
| 2022 |
Budelier MM, He Y, Barthelemy NR, Jiang H, Li Y, Park E, Henson RL, Schindler SE, Holtzman DM, Bateman RJ. A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer's disease. Brain Communications. 4: fcac045. PMID 35415607 DOI: 10.1093/braincomms/fcac045 |
0.5 |
|
| 2022 |
Strain JF, Barthelemy N, Horie K, Gordon BA, Kilgore C, Aschenbrenner A, Cruchaga C, Xiong C, Joseph-Mathurin N, Hassenstab J, Fagan AM, Li Y, Karch CM, Perrin RJ, Berman SB, ... ... Holtzman DM, et al. CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease. 168: 105714. PMID 35358703 DOI: 10.1016/j.nbd.2022.105714 |
0.71 |
|
| 2022 |
Doherty JM, Roe CM, Murphy SA, Johnson AM, Fleischer E, Toedebusch CD, Redrick T, Freund D, Morris JC, Schindler SE, Fagan AM, Holtzman DM, Lucey BP, Babulal GM. Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer's disease. Sleep. PMID 35303111 DOI: 10.1093/sleep/zsac070 |
0.301 |
|
| 2022 |
Martens YA, Zhao N, Liu CC, Kanekiyo T, Yang AJ, Goate AM, Holtzman DM, Bu G. ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias. Neuron. PMID 35298921 DOI: 10.1016/j.neuron.2022.03.004 |
0.342 |
|
| 2022 |
Gratuze M, Jiang H, Wang C, Xiong M, Bao X, Holtzman DM. APOE Antibody Inhibits Aβ-Associated Tau Seeding and Spreading in a Mouse Model. Annals of Neurology. PMID 35285073 DOI: 10.1002/ana.26351 |
0.807 |
|
| 2022 |
Parhizkar S, Holtzman DM. APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease. Seminars in Immunology. 101594. PMID 35232622 DOI: 10.1016/j.smim.2022.101594 |
0.432 |
|
| 2022 |
Mann CN, Devi SS, Kersting CT, Bleem AV, Karch CM, Holtzman DM, Gallardo G. Astrocytic α2-Na/K ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model. Science Translational Medicine. 14: eabm4107. PMID 35171651 DOI: 10.1126/scitranslmed.abm4107 |
0.387 |
|
| 2022 |
Mahan TE, Wang C, Bao X, Choudhury A, Ulrich JD, Holtzman DM. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis. Molecular Neurodegeneration. 17: 13. PMID 35109920 DOI: 10.1186/s13024-022-00516-0 |
0.831 |
|
| 2022 |
Bigley TM, Xiong M, Ali M, Chen Y, Wang C, Serrano JR, Eteleeb A, Harari O, Yang L, Patel SJ, Cruchaga C, Yokoyama WM, Holtzman DM. Murine roseolovirus does not accelerate amyloid-β pathology and human roseoloviruses are not over-represented in Alzheimer disease brains. Molecular Neurodegeneration. 17: 10. PMID 35033173 DOI: 10.1186/s13024-021-00514-8 |
0.404 |
|
| 2021 |
Mehla J, Singh I, Diwan D, Nelson JW, Lawrence M, Lee E, Bauer AQ, Holtzman DM, Zipfel GJ. STAT3 inhibitor mitigates cerebral amyloid angiopathy and parenchymal amyloid plaques while improving cognitive functions and brain networks. Acta Neuropathologica Communications. 9: 193. PMID 34911575 DOI: 10.1186/s40478-021-01293-5 |
0.389 |
|
| 2021 |
Musiek ES, Gomez-Isla T, Holtzman DM. Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside. The Journal of Clinical Investigation. 131. PMID 34651585 DOI: 10.1172/JCI154889 |
0.407 |
|
| 2021 |
Schindler S, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, Coble D, Klunk WE, Fagan AM, Holtzman D, Bateman RJ, Morris JC, Xiong C. Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology. PMID 34504028 DOI: 10.1212/WNL.0000000000012775 |
0.549 |
|
| 2021 |
Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34385305 DOI: 10.1073/pnas.2102191118 |
0.359 |
|
| 2021 |
Chen X, Sun G, Tian E, Zhang M, Davtyan H, Beach TG, Reiman EM, Blurton-Jones M, Holtzman DM, Shi Y. Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). e2101462. PMID 34337898 DOI: 10.1002/advs.202101462 |
0.417 |
|
| 2021 |
McDade E, Llibre-Guerra JJ, Holtzman DM, Morris JC, Bateman RJ. The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration. 16: 49. PMID 34289882 DOI: 10.1186/s13024-021-00467-y |
0.559 |
|
| 2021 |
Shi Y, Andhey PS, Ising C, Wang K, Snipes LL, Boyer K, Lawson S, Yamada K, Qin W, Manis M, Serrano JR, Benitez BA, Schmidt RE, Artyomov M, Ulrich JD, ... Holtzman DM, et al. Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. Neuron. PMID 34157306 DOI: 10.1016/j.neuron.2021.05.034 |
0.351 |
|
| 2021 |
Lall D, Lorenzini I, Mota TA, Bell S, Mahan TE, Ulrich JD, Davtyan H, Rexach JE, Muhammad AKMG, Shelest O, Landeros J, Vazquez M, Kim J, Ghaffari L, O'Rourke JG, ... ... Holtzman DM, et al. C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation. Neuron. PMID 34133945 DOI: 10.1016/j.neuron.2021.05.020 |
0.78 |
|
| 2021 |
Gratuze M, Chen Y, Parhizkar S, Jain N, Strickland MR, Serrano JR, Colonna M, Ulrich JD, Holtzman DM. Activated microglia mitigate Aβ-associated tau seeding and spreading. The Journal of Experimental Medicine. 218. PMID 34100905 DOI: 10.1084/jem.20210542 |
0.802 |
|
| 2021 |
Butt OH, Meeker KL, Wisch JK, Schindler SE, Fagan AM, Benzinger TLS, Cruchaga C, Holtzman DM, Morris JC, Ances BM. Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34002449 DOI: 10.1002/alz.12375 |
0.413 |
|
| 2021 |
Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, Nixon RA, Jones DT. Alzheimer disease. Nature Reviews. Disease Primers. 7: 33. PMID 33986301 DOI: 10.1038/s41572-021-00269-y |
0.413 |
|
| 2021 |
West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Contois JH, Jackson EN, Harpstrite SE, Bateman RJ, Holtzman DM, Verghese PB, Fogelman I, Braunstein JB, Yarasheski KE. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Molecular Neurodegeneration. 16: 30. PMID 33933117 DOI: 10.1186/s13024-021-00451-6 |
0.822 |
|
| 2021 |
Da Mesquita S, Papadopoulos Z, Dykstra T, Brase L, Farias FG, Wall M, Jiang H, Kodira CD, de Lima KA, Herz J, Louveau A, Goldman DH, Salvador AF, Onengut-Gumuscu S, Farber E, ... ... Holtzman DM, et al. Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy. Nature. PMID 33911285 DOI: 10.1038/s41586-021-03489-0 |
0.679 |
|
| 2021 |
Spears LD, Adak S, Dong G, Wei X, Spyropoulos G, Zhang Q, Yin L, Feng C, Hu D, Lodhi IJ, Hsu FF, Rajagopal R, Noguchi KK, Halabi CM, Brier L, ... ... Holtzman DM, et al. Endothelial ether lipids link the vasculature to blood pressure, behavior, and neurodegeneration. Journal of Lipid Research. 100079. PMID 33894211 DOI: 10.1016/j.jlr.2021.100079 |
0.508 |
|
| 2021 |
Wang C, Xiong M, Gratuze M, Bao X, Shi Y, Andhey PS, Manis M, Schroeder C, Yin Z, Madore C, Butovsky O, Artyomov M, Ulrich JD, Holtzman DM. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron. PMID 33831349 DOI: 10.1016/j.neuron.2021.03.024 |
0.772 |
|
| 2021 |
Butt OH, Long JM, Henson RL, Herries E, Sutphen CL, Fagan AM, Cruchaga C, Ladenson JH, Holtzman DM, Morris JC, Ances BM, Schindler SE. Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25. Neurobiology of Aging. 102: 64-72. PMID 33765432 DOI: 10.1016/j.neurobiolaging.2021.02.008 |
0.373 |
|
| 2021 |
Gratuze M, Holtzman DM. Targeting pre-synaptic tau accumulation: a new strategy to counteract tau-mediated synaptic loss and memory deficits. Neuron. 109: 741-743. PMID 33662267 DOI: 10.1016/j.neuron.2021.02.014 |
0.711 |
|
| 2021 |
Xiong M, Jiang H, Serrano JR, Gonzales ER, Wang C, Gratuze M, Hoyle R, Bien-Ly N, Silverman AP, Sullivan PM, Watts RJ, Ulrich JD, Zipfel GJ, Holtzman DM. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Science Translational Medicine. 13. PMID 33597265 DOI: 10.1126/scitranslmed.abd7522 |
0.791 |
|
| 2021 |
Litvinchuk A, Huynh TV, Shi Y, Jackson RJ, Finn MB, Manis M, Francis CM, Tran A, Sullivan PM, Ulrich JD, Hyman BT, Cole T, Holtzman DM. ApoE4 reduction with ASOs decreases neurodegeneration in a tauopathy model. Annals of Neurology. PMID 33550655 DOI: 10.1002/ana.26043 |
0.38 |
|
| 2021 |
Smith R, Strain J, Tanenbaum A, Fagan A, Hassenstab J, Mcdade E, Schindler S, Gordon B, Xiong C, Chhatwal J, Jack CR, Karch C, Berman S, Brosch J, Lah J, ... ... Holtzman D, et al. Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity. PMID 33430685 DOI: 10.1089/brain.2020.0808 |
0.508 |
|
| 2020 |
Krishnan N, Chen X, Donnelly-Roberts D, Mohler EG, Holtzman DM, Gopalakrishnan SM. Small Molecule Phenotypic Screen Identifies Novel Regulators of LDLR Expression. Acs Chemical Biology. PMID 33270420 DOI: 10.1021/acschembio.0c00851 |
0.542 |
|
| 2020 |
Chen Y, Strickland MR, Soranno A, Holtzman DM. Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis. Neuron. PMID 33176118 DOI: 10.1016/j.neuron.2020.10.008 |
0.376 |
|
| 2020 |
Carare RO, Aldea R, Agarwal N, Bacskai BJ, Bechman I, Boche D, Bu G, Bulters D, Clemens A, Counts SE, de Leon M, Eide PK, Fossati S, Greenberg SM, Hamel E, ... ... Holtzman D, et al. Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA): Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's disease-Opportunities for Therapy. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12053. PMID 32775596 DOI: 10.1002/Dad2.12053 |
0.478 |
|
| 2020 |
Wong MY, Lewis M, Doherty JJ, Shi Y, Cashikar AG, Amelianchik A, Tymchuk S, Sullivan PM, Qian M, Covey DF, Petsko GA, Holtzman DM, Paul SM, Luo W. 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner. Journal of Neuroinflammation. 17: 192. PMID 32552741 DOI: 10.1186/S12974-020-01869-3 |
0.37 |
|
| 2020 |
Gratuze M, Leyns CE, Sauerbeck AD, St-Pierre MK, Xiong M, Kim N, Remolina Serrano J, Tremblay MÈ, Kummer TT, Colonna M, Ulrich JD, Holtzman DM. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. The Journal of Clinical Investigation. PMID 32544086 DOI: 10.1172/Jci138179 |
0.851 |
|
| 2020 |
Cable J, Holtzman DM, Hyman BT, Tansey MG, Colonna M, Kellis M, Brinton RD, Albert M, Wellington CL, Sisodia SS, Tanzi RE. Alternatives to amyloid for Alzheimer's disease therapies-a symposium report. Annals of the New York Academy of Sciences. PMID 32472577 DOI: 10.1111/Nyas.14371 |
0.326 |
|
| 2020 |
Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, Cella M, Ulland TK, Zaitsev K, Miyashita A, Ikeuchi T, ... ... Holtzman DM, et al. Author Correction: Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nature Medicine. PMID 32409732 DOI: 10.1038/S41591-020-0922-4 |
0.688 |
|
| 2020 |
Sauerbeck AD, Gangolli M, Reitz SJ, Salyards MH, Kim SH, Hemingway C, Gratuze M, Makkapati T, Kerschensteiner M, Holtzman DM, Brody DL, Kummer TT. SEQUIN Multiscale Imaging of Mammalian Central Synapses Reveals Loss of Synaptic Connectivity Resulting from Diffuse Traumatic Brain Injury. Neuron. PMID 32392471 DOI: 10.1016/J.Neuron.2020.04.012 |
0.702 |
|
| 2020 |
Xu Y, Du S, Marsh JA, Horie K, Sato C, Ballabio A, Karch CM, Holtzman DM, Zheng H. TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading. Molecular Psychiatry. PMID 32366951 DOI: 10.1038/S41380-020-0738-0 |
0.599 |
|
| 2020 |
Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A, Haines JN, Dhavale DD, Miller R, Choudhury FA, Sullivan PM, Cruchaga C, Perlmutter JS, Ulrich JD, Benitez BA, ... ... Holtzman DM, et al. genotype regulates pathology and disease progression in synucleinopathy. Science Translational Medicine. 12. PMID 32024799 DOI: 10.1126/Scitranslmed.Aay3069 |
0.329 |
|
| 2020 |
Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, Cella M, Ulland TK, Zaitsev K, Miyashita A, Ikeuchi T, ... ... Holtzman DM, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nature Medicine. 26: 131-142. PMID 31932797 DOI: 10.1038/S41591-019-0695-9 |
0.753 |
|
| 2020 |
Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L, Xiong C, Morris JC, Benzinger TLS, Holtzman DM. Erratum: Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease (Science Translational Medicine DOI: 10.1126/scitranslmed.aau6550) Science Translational Medicine. 12. PMID 31915302 DOI: 10.1126/Scitranslmed.Aba5187 |
0.365 |
|
| 2019 |
Gallardo G, Holtzman DM. Amyloid-β and Tau at the Crossroads of Alzheimer's Disease. Advances in Experimental Medicine and Biology. 1184: 187-203. PMID 32096039 DOI: 10.1007/978-981-32-9358-8_16 |
0.423 |
|
| 2019 |
Jack CR, Holtzman DM, Sperling R. Dementia is not synonymous with Alzheimer's disease. Science Translational Medicine. 11. PMID 31826979 DOI: 10.1126/Scitranslmed.Aav0511 |
0.321 |
|
| 2019 |
Llibre-Guerra JJ, Li Y, Schindler SE, Gordon BA, Fagan AM, Morris JC, Benzinger TLS, Hassenstab J, Wang G, Allegri R, Berman SB, Chhatwal J, Farlow MR, Holtzman DM, Jucker M, et al. Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. Jama Network Open. 2: e1917126. PMID 31825500 DOI: 10.1001/jamanetworkopen.2019.17126 |
0.567 |
|
| 2019 |
Seo DO, Holtzman DM. Gut microbiota: from the forgotten organ to a potential key player in the pathology of Alzheimer disease. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. PMID 31738402 DOI: 10.1093/gerona/glz262 |
0.353 |
|
| 2019 |
Gallardo G, Wong CH, Ricardez SM, Mann CN, Lin KH, Leyns CEG, Jiang H, Holtzman DM. Targeting tauopathy with engineered tau-degrading intrabodies. Molecular Neurodegeneration. 14: 38. PMID 31640765 DOI: 10.1186/S13024-019-0340-6 |
0.31 |
|
| 2019 |
Huynh TV, Wang C, Tran AC, Tabor GT, Mahan TE, Francis CM, Finn MB, Spellman R, Manis M, Tanzi RE, Ulrich JD, Holtzman DM. Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model. Molecular Neurodegeneration. 14: 37. PMID 31623648 DOI: 10.1186/S13024-019-0337-1 |
0.831 |
|
| 2019 |
Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, Hoyle R, Holtzman DM. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. The Journal of Experimental Medicine. PMID 31601677 DOI: 10.1084/Jem.20190980 |
0.399 |
|
| 2019 |
Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 179: 312-339. PMID 31564456 DOI: 10.1016/J.Cell.2019.09.001 |
0.367 |
|
| 2019 |
Xu J, Sun J, Perrin RJ, Mach RH, Bales KR, Morris JC, Benzinger TLS, Holtzman DM. Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains. Annals of Clinical and Translational Neurology. 6: 1423-1434. PMID 31402620 DOI: 10.1002/Acn3.50837 |
0.67 |
|
| 2019 |
Del-Aguila JL, Li Z, Dube U, Mihindukulasuriya KA, Budde JP, Fernandez MV, Ibanez L, Bradley J, Wang F, Bergmann K, Davenport R, Morris JC, Holtzman DM, Perrin RJ, Benitez BA, et al. A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimer's Research & Therapy. 11: 71. PMID 31399126 DOI: 10.1186/S13195-019-0524-X |
0.668 |
|
| 2019 |
Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. PMID 31371569 DOI: 10.1212/Wnl.0000000000008081 |
0.612 |
|
| 2019 |
Leyns CEG, Gratuze M, Narasimhan S, Jain N, Koscal LJ, Jiang H, Manis M, Colonna M, Lee VMY, Ulrich JD, Holtzman DM. TREM2 function impedes tau seeding in neuritic plaques. Nature Neuroscience. PMID 31235932 DOI: 10.1038/S41593-019-0433-0 |
0.797 |
|
| 2019 |
Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, Chavez-Gutierrez L, Cleverley K, Noy S, Sheppard O, Collins T, Powell C, Sarell CJ, Rickman M, Choong X, ... ... Holtzman DM, et al. Trisomy of human chromosome 21 enhances amyloid-beta 3 deposition independently of an extra copy of APP (vol 141, pg 2457, 2018) Brain. 142. PMID 30879033 DOI: 10.1093/Brain/Awz061 |
0.334 |
|
| 2019 |
Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ, Hassenstab JJ, Benzinger TLS, Cruchaga C, Jucker M, Levin J, ... ... Holtzman DM, et al. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30846386 DOI: 10.1016/J.Jalz.2018.12.019 |
0.598 |
|
| 2019 |
Patel TK, Habimana-Griffin L, Gao X, Xu B, Achilefu S, Alitalo K, McKee CA, Sheehan PW, Musiek ES, Xiong C, Coble D, Holtzman DM. Dural lymphatics regulate clearance of extracellular tau from the CNS. Molecular Neurodegeneration. 14: 11. PMID 30813965 DOI: 10.1186/S13024-019-0312-X |
0.513 |
|
| 2019 |
Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR, ... ... Holtzman DM, et al. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. Brain : a Journal of Neurology. PMID 30753379 DOI: 10.1093/Brain/Awz019 |
0.617 |
|
| 2019 |
Strickland MR, Holtzman DM. Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1. The Journal of Clinical Investigation. PMID 30741722 DOI: 10.1172/JCI127578 |
0.426 |
|
| 2019 |
Ju YS, Holtzman DM. Reply to "Obstructive sleep apnea treatment and amyloid-β in cerebrospinal fluid". Annals of Neurology. PMID 30706528 DOI: 10.1002/Ana.25424 |
0.554 |
|
| 2019 |
Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling JC, Fuller PM, Lucey BP, Holtzman DM. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science (New York, N.Y.). PMID 30679382 DOI: 10.1126/Science.Aav2546 |
0.828 |
|
| 2019 |
Jagust W, Jack CR, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, et al. "Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia". Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 15: 153-157. PMID 30642435 DOI: 10.1016/J.Jalz.2018.11.002 |
0.422 |
|
| 2019 |
Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L, Xiong C, Morris JC, Benzinger TLS, Holtzman DM. Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. Science Translational Medicine. 11. PMID 30626715 DOI: 10.1126/Scitranslmed.Aau6550 |
0.388 |
|
| 2019 |
Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Müller SA, Colombo A, Monasor LS, ... ... Holtzman DM, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nature Neuroscience. PMID 30617257 DOI: 10.1038/S41593-018-0296-9 |
0.399 |
|
| 2019 |
Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, Xiong C. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. Jama Neurology. PMID 30615028 DOI: 10.1001/Jamaneurol.2018.4249 |
0.408 |
|
| 2019 |
Li Y, Schindler SE, Llibre Guerra JJ, Bollinger JG, Ovod V, Mawuenyega KG, Gordon BA, Holtzman DM, Morris JC, Benzinger TL, Xiong C, Fagan AM, Bateman R. PLASMA Aβ42/Aβ40 PREDICTS HIPPOCAMPAL ATROPHY Alzheimer's & Dementia. 15: P191-P192. DOI: 10.1016/J.Jalz.2019.06.4519 |
0.57 |
|
| 2019 |
Florian H, Arnold SE, Bateman R, Braunstein JB, Budur K, Kerwin DR, Soares H, Wang D, Holtzman DM. ABBV-8E12, A HUMANIZED ANTI-TAU MONOCLONAL ANTIBODY, FOR TREATING EARLY ALZHEIMER’S DISEASE: UPDATED DESIGN AND BASELINE CHARACTERISTICS OF A PHASE 2 STUDY Alzheimer's & Dementia. 15: P251-P252. DOI: 10.1016/J.Jalz.2019.06.075 |
0.508 |
|
| 2018 |
Ju YS, Zangrilli MA, Finn MB, Fagan AM, Holtzman DM. Obstructive sleep apnea treatment, slow wave activity, and amyloid-β. Annals of Neurology. PMID 30597615 DOI: 10.1002/Ana.25408 |
0.64 |
|
| 2018 |
Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer's disease. Molecular Neurodegeneration. 13: 66. PMID 30572908 DOI: 10.1186/S13024-018-0298-9 |
0.806 |
|
| 2018 |
Huynh TV, Holtzman DM. Amyloid-β 'seeds' in old vials of growth hormone. Nature. 564: 354-355. PMID 30546137 DOI: 10.1038/D41586-018-07604-6 |
0.395 |
|
| 2018 |
Babulal GM, Chen S, Williams MM, Trani JF, Bakhshi P, Chao GL, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, Morris JC, Roe CM. Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. Journal of Alzheimer's Disease : Jad. PMID 30400098 DOI: 10.3233/Jad-180564 |
0.39 |
|
| 2018 |
Lessard CB, Malnik SL, Zhou Y, Ladd TB, Cruz PE, Ran Y, Mahan TE, Chakrabaty P, Holtzman DM, Ulrich JD, Colonna M, Golde TE. High-affinity interactions and signal transduction between Aβ oligomers and TREM2. Embo Molecular Medicine. PMID 30341064 DOI: 10.15252/Emmm.201809027 |
0.829 |
|
| 2018 |
Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Molecular Neurodegeneration. 13: 57. PMID 30340601 DOI: 10.1186/S13024-018-0286-0 |
0.776 |
|
| 2018 |
Roe CM, Ances BM, Head D, Babulal GM, Stout SH, Grant EA, Hassenstab J, Xiong C, Holtzman DM, Benzinger TLS, Schindler SE, Fagan AM, Morris JC. Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain : a Journal of Neurology. PMID 30304397 DOI: 10.1093/Brain/Awy244 |
0.327 |
|
| 2018 |
McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. PMID 30217935 DOI: 10.1212/Wnl.0000000000006277 |
0.535 |
|
| 2018 |
Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nature Reviews. Immunology. PMID 30140051 DOI: 10.1038/S41577-018-0051-1 |
0.433 |
|
| 2018 |
Huynh TV, Holtzman DM. In Search of an Identity for Amyloid Plaques. Trends in Neurosciences. 41: 483-486. PMID 30053949 DOI: 10.1016/J.Tins.2018.06.002 |
0.465 |
|
| 2018 |
Davis AA, Leyns CEG, Holtzman DM. Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. Annual Review of Cell and Developmental Biology. PMID 30044648 DOI: 10.1146/Annurev-Cellbio-100617-062636 |
0.348 |
|
| 2018 |
Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, Chávez-Gutiérrez L, Cleverley K, Noy S, Sheppard O, Collins T, Powell C, Sarell CJ, Rickman M, Choong X, ... ... Holtzman DM, et al. Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP. Brain : a Journal of Neurology. PMID 29945247 DOI: 10.1093/Brain/Awy159 |
0.438 |
|
| 2018 |
Roe CM, Babulal GM, Stout SH, Ott BR, Carr DB, Williams MM, Benzinger TLS, Fagan AM, Holtzman DM, Ances BM, Morris JC. Using the A/T/N Framework to Examine Driving in Preclinical AD. Geriatrics (Basel, Switzerland). 3. PMID 29805967 DOI: 10.3390/Geriatrics3020023 |
0.446 |
|
| 2018 |
Hettinger JC, Lee H, Bu G, Holtzman DM, Cirrito JR. AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model. Molecular Neurodegeneration. 13: 22. PMID 29764453 DOI: 10.1186/S13024-018-0256-6 |
0.717 |
|
| 2018 |
Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, et al. White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. Plos One. 13: e0195838. PMID 29742105 DOI: 10.1371/Journal.Pone.0195838 |
0.614 |
|
| 2018 |
Patel TK, Holtzman DM. Dual therapy for Aβ amyloidosis in AD: A successful one-two combo. The Journal of Experimental Medicine. PMID 29685951 DOI: 10.1084/Jem.20180494 |
0.462 |
|
| 2018 |
Mishra S, Blazey TM, Holtzman DM, Cruchaga C, Su Y, Morris JC, Benzinger TLS, Gordon BA. Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ɛ4 genotype. Brain : a Journal of Neurology. PMID 29672664 DOI: 10.1093/Brain/Awy103 |
0.455 |
|
| 2018 |
Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 14: 535-562. PMID 29653606 DOI: 10.1016/J.Jalz.2018.02.018 |
0.455 |
|
| 2018 |
Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, Finn MB, Hoyle R, Keyser J, Lefton KB, Robinson GO, Serrano JR, Silverman AP, Guo JL, Getz J, ... ... Holtzman DM, et al. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. The Journal of Clinical Investigation. PMID 29600961 DOI: 10.1172/Jci96429 |
0.846 |
|
| 2018 |
Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, Fagan AM. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29580670 DOI: 10.1016/J.Jalz.2018.01.012 |
0.382 |
|
| 2018 |
Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, Wahl S, Benzinger TLS, Holtzman DM, Morris JC, Fagan AM. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29501462 DOI: 10.1016/J.Jalz.2018.01.013 |
0.463 |
|
| 2018 |
Ulrich JD, Ulland TK, Mahan TE, Nyström S, Nilsson KP, Song WM, Zhou Y, Reinartz M, Choi S, Jiang H, Stewart FR, Anderson E, Wang Y, Colonna M, Holtzman DM. ApoE facilitates the microglial response to amyloid plaque pathology. The Journal of Experimental Medicine. PMID 29483128 DOI: 10.1084/Jem.20171265 |
0.858 |
|
| 2018 |
Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR, ... ... Holtzman DM, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. The Lancet. Neurology. PMID 29397305 DOI: 10.1016/S1474-4422(18)30028-0 |
0.615 |
|
| 2018 |
Kress GJ, Liao F, Dimitry J, Cedeno MR, FitzGerald GA, Holtzman DM, Musiek ES. Regulation of amyloid-β dynamics and pathology by the circadian clock. The Journal of Experimental Medicine. PMID 29382695 DOI: 10.1084/Jem.20172347 |
0.493 |
|
| 2018 |
Musiek ES, Bhimasani M, Zangrilli MA, Morris JC, Holtzman DM, Ju YS. Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. Jama Neurology. PMID 29379963 DOI: 10.1001/Jamaneurol.2017.4719 |
0.629 |
|
| 2018 |
Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, Craft S, Gandy S, Buettner C, Stoeckel LE, Holtzman DM, Nathan DM. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nature Reviews. Neurology. PMID 29377010 DOI: 10.1038/Nrneurol.2017.185 |
0.312 |
|
| 2018 |
Stout SH, Babulal GM, Ma C, Carr DB, Head DM, Grant EA, Williams MM, Holtzman DM, Fagan AM, Morris JC, Roe CM. Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29328928 DOI: 10.1016/J.Jalz.2017.11.011 |
0.399 |
|
| 2017 |
Huynh TV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, Roh J, Finn MB, Sullivan PM, Esparza TJ, Stewart FR, Mahan TE, Ulrich JD, Cole T, Holtzman DM. Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis. Neuron. 96: 1013-1023.e4. PMID 29216448 DOI: 10.1016/J.Neuron.2017.11.014 |
0.834 |
|
| 2017 |
West T, Hu Y, Verghese PB, Bateman RJ, Braunstein JB, Fogelman I, Budur K, Florian H, Mendonca N, Holtzman DM. Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies. The Journal of Prevention of Alzheimer's Disease. 4: 236-241. PMID 29181488 DOI: 10.14283/jpad.2017.36 |
0.756 |
|
| 2017 |
Andrew RJ, Fernandez CG, Stanley M, Jiang H, Nguyen P, Rice RC, Buggia-Prévot V, De Rossi P, Vetrivel KS, Lamb R, Argemi A, Allaert ES, Rathbun EM, Krause SV, Wagner SL, ... ... Holtzman DM, et al. Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 29078331 DOI: 10.1073/Pnas.1708568114 |
0.438 |
|
| 2017 |
Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, Holtzman DM. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proceedings of the National Academy of Sciences of the United States of America. 114: 11524-11529. PMID 29073081 DOI: 10.1073/Pnas.1710311114 |
0.482 |
|
| 2017 |
Kang SS, Kurti A, Baker KE, Liu CC, Colonna M, Ulrich JD, Holtzman DM, Bu G, Fryer JD. Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal. Human Molecular Genetics. PMID 29040522 DOI: 10.1093/Hmg/Ddx366 |
0.388 |
|
| 2017 |
Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, ... ... Holtzman DM, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 549: 523-527. PMID 28959956 DOI: 10.1038/Nature24016 |
0.372 |
|
| 2017 |
Cruchaga C, Del-Aguila JL, Saef B, Black K, Fernandez MV, Budde J, Ibanez L, Kapoor M, Tosto G, Mayeux RP, Holtzman DM, Fagan AM, Morris JC, Bateman RJ, Goate AM, et al. Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28943286 DOI: 10.1016/J.Jalz.2017.08.013 |
0.596 |
|
| 2017 |
Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, ... ... Holtzman DM, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. 47: 566-581.e9. PMID 28930663 DOI: 10.1016/J.Immuni.2017.08.008 |
0.508 |
|
| 2017 |
Ju YS, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, Fagan AM, Mignot E, Zempel JM, Claassen JAHR, Holtzman DM. Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels. Brain : a Journal of Neurology. 140: 2104-2111. PMID 28899014 DOI: 10.1093/Brain/Awx148 |
0.547 |
|
| 2017 |
Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, Loginicheva E, Gilfillan S, Cella M, Virgin HW, Unanue ER, ... ... Holtzman DM, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell. 170: 649-663.e13. PMID 28802038 DOI: 10.1016/J.Cell.2017.07.023 |
0.757 |
|
| 2017 |
Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman RJ. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28734653 DOI: 10.1016/J.Jalz.2017.06.2266 |
0.585 |
|
| 2017 |
Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, Mulder SD, Scheltens P, Xiong C, Fagan AM. Upward drift in cerebrospinal fluid amyloid-β 42 assay values for more than 10 years. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28710906 DOI: 10.1016/J.Jalz.2017.06.2264 |
0.482 |
|
| 2017 |
Leyns CEG, Holtzman DM. Glial contributions to neurodegeneration in tauopathies. Molecular Neurodegeneration. 12: 50. PMID 28662669 DOI: 10.1186/S13024-017-0192-X |
0.528 |
|
| 2017 |
Ising C, Gallardo G, Leyns CEG, Wong CH, Jiang H, Stewart F, Koscal LJ, Roh J, Robinson GO, Serrano JR, Holtzman DM. Correction: AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. The Journal of Experimental Medicine. PMID 28536241 DOI: 10.1084/Jem.2016212505192017C |
0.395 |
|
| 2017 |
Schindler SE, Jasielec MS, Weng H, Hassenstab JJ, Grober E, McCue LM, Morris JC, Holtzman DM, Xiong C, Fagan AM. Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Neurobiology of Aging. 56: 25-32. PMID 28482211 DOI: 10.1016/J.Neurobiolaging.2017.04.004 |
0.304 |
|
| 2017 |
Lucey BP, Fagan AM, Holtzman DM, Morris JC, Bateman RJ. Diurnal oscillation of CSF Aβ and other AD biomarkers. Molecular Neurodegeneration. 12: 36. PMID 28478762 DOI: 10.1186/S13024-017-0161-4 |
0.61 |
|
| 2017 |
Babulal GM, Stout SH, Head D, Holtzman DM, Fagan AM, Morris JC, Roe CM. Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report. Journal of Alzheimer's Disease : Jad. PMID 28453487 DOI: 10.3233/Jad-170067 |
0.447 |
|
| 2017 |
Roe CM, Babulal GM, Head DM, Stout SH, Vernon EK, Ghoshal N, Garland B, Barco PP, Williams MM, Johnson A, Fierberg R, Fague MS, Xiong C, Mormino E, Grant EA, ... Holtzman DM, et al. Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimer's & Dementia (New York, N. Y.). 3: 74-82. PMID 28435853 DOI: 10.1016/J.Trci.2016.11.006 |
0.414 |
|
| 2017 |
Ulrich JD, Ulland TK, Colonna M, Holtzman DM. Elucidating the Role of TREM2 in Alzheimer's Disease. Neuron. 94: 237-248. PMID 28426958 DOI: 10.1016/J.Neuron.2017.02.042 |
0.769 |
|
| 2017 |
Yanamandra K, Patel TK, Jiang H, Schindler S, Ulrich JD, Boxer AL, Miller BL, Kerwin DR, Gallardo G, Stewart F, Finn MB, Cairns NJ, Verghese PB, Fogelman I, West T, ... ... Holtzman DM, et al. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Science Translational Medicine. 9. PMID 28424326 DOI: 10.1126/Scitranslmed.Aal2029 |
0.785 |
|
| 2017 |
Ising C, Gallardo G, Leyns CEG, Wong CH, Stewart F, Koscal LJ, Roh J, Robinson GO, Remolina Serrano J, Holtzman DM. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. The Journal of Experimental Medicine. PMID 28416651 DOI: 10.1084/Jem.20162125 |
0.361 |
|
| 2017 |
Holth JK, Mahan TE, Robinson GO, Rocha A, Holtzman DM. Altered sleep and EEG power in the P301S Tau transgenic mouse model. Annals of Clinical and Translational Neurology. 4: 180-190. PMID 28275652 DOI: 10.1002/Acn3.390 |
0.764 |
|
| 2017 |
Liu CC, Hu J, Zhao N, Wang J, Na W, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G. Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28275161 DOI: 10.1523/Jneurosci.3442-16.2017 |
0.707 |
|
| 2017 |
Deming Y, Li Z, Kapoor M, Harari O, Del-Aguila JL, Black K, Carrell D, Cai Y, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Huang KL, Bertelsen S, ... ... Holtzman DM, et al. Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. Acta Neuropathologica. PMID 28247064 DOI: 10.1007/s00401-017-1685-y |
0.345 |
|
| 2017 |
Huynh TV, Davis AA, Ulrich JD, Holtzman DM. Apolipoprotein E and Alzheimer Disease: The influence of apoE on amyloid-β and other amyloidogenic proteins. Journal of Lipid Research. PMID 28246336 DOI: 10.1194/Jlr.R075481 |
0.544 |
|
| 2017 |
Ooms SJ, Zempel JM, Holtzman DM, Ju YS. Automated selective disruption of slow wave sleep. Journal of Neuroscience Methods. PMID 28238859 DOI: 10.1016/J.Jneumeth.2017.02.008 |
0.501 |
|
| 2017 |
Holth J, Patel T, Holtzman DM. Sleep in Alzheimer's Disease - Beyond Amyloid. Neurobiology of Sleep and Circadian Rhythms. 2: 4-14. PMID 28217760 DOI: 10.1016/J.Nbscr.2016.08.002 |
0.416 |
|
| 2017 |
Pankiewicz JE, Baquero-Buitrago J, Sanchez S, Lopez-Contreras J, Kim J, Sullivan PM, Holtzman DM, Sadowski MJ. APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice. Molecular Neurodegeneration. 12: 12. PMID 28143566 DOI: 10.1186/S13024-017-0156-1 |
0.689 |
|
| 2017 |
Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takano T, Holtzman DM, Nedergaard M, Deane R. Erratum to: Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Molecular Neurodegeneration. 12: 3. PMID 28081701 DOI: 10.1186/s13024-016-0147-7 |
0.668 |
|
| 2017 |
Gallardo G, Holtzman DM. Antibody Therapeutics Targeting Aβ and Tau. Cold Spring Harbor Perspectives in Medicine. PMID 28062555 DOI: 10.1101/cshperspect.a024331 |
0.386 |
|
| 2017 |
Ovod V, Bollinger JG, Mawuenyega KG, Hicks TJ, Schneider T, Kasten T, Sigurdson W, Sullivan M, Donahue TA, Ramsey K, Paumier KL, Holtzman DM, Morris JC, Benzinger TL, Fagan AM, et al. CONCENTRATIONS AND STABLE ISOTOPE LABEL KINETICS OF HUMAN PLASMA AMYLOID BETA Alzheimer's & Dementia. 13: P1475-P1476. DOI: 10.1016/J.Jalz.2017.08.005 |
0.5 |
|
| 2017 |
Holtzman DM. EFFECTS OF SYNAPTIC ACTIVITY ON Aβ AND TAU FROM PRECLINICAL IN VIVO STUDIES: SIMILARITIES, DIFFERENCES, AND IMPLICATIONS Alzheimer's & Dementia. 13: P1215. DOI: 10.1016/J.Jalz.2017.07.387 |
0.405 |
|
| 2017 |
McDade E, Wang G, Benzinger TL, Buckles VD, Fagan AM, Gordon BA, Hassenstab J, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier KL, Xiong C, Ricardo A, et al. LONGITUDINAL BIOMARKER CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE FROM THE DIAN STUDY Alzheimer's & Dementia. 13: P879-P880. DOI: 10.1016/J.Jalz.2017.07.265 |
0.573 |
|
| 2017 |
Budur K, West T, Braunstein JB, Fogelman I, Bordelon YM, Litvan I, Roberson ED, Hu H, Verghese PB, Bateman RJ, Florian H, Wang D, Ryman D, Gault L, Goss S, ... ... Holtzman DM, et al. [O2-17-01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO-CONTROLLED STUDY OF ABBV-8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE Alzheimer's & Dementia. 13: P599-P600. DOI: 10.1016/J.Jalz.2017.07.241 |
0.753 |
|
| 2017 |
Roe CM, Babulal GM, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, Ott BR, Carr DB, Xiong C, Morris JC. Impact Of Cognitive Reserve And Preclinical Ad On Longitudinal Driving Performance Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.07.147 |
0.35 |
|
| 2017 |
Deming Y, Kapoor M, Li Z, Harari O, Black K, Del-Aguila JL, Carrell D, Cai Y, Fernandez MV, Budde JP, Ma S, Saef B, Howells B, Huang K, Bertelsen S, ... ... Holtzman DM, et al. CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE Alzheimer's & Dementia. 13: P218-P219. DOI: 10.1016/J.Jalz.2017.07.096 |
0.416 |
|
| 2017 |
Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, Chavez-Gutierrez L, Cleverley K, Noy S, Rickman M, Tosh J, Whittaker H, Stewart F, Szaruga M, Nizetic D, ... ... Holtzman DM, et al. TRISOMY 21 CAUSES A DEFICIT IN LYSOSOMAL CATHEPSINS AND ALTERS APP/Aβ PROCESSING, INDEPENDENTLY OF AN EXTRA COPY OF APP Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.791 |
0.422 |
|
| 2017 |
Li A, Jiang H, Lefton K, Robinson GO, Sullivan PM, Roh JD, Holtzman DM. [P1-167]: AAV-MEDIATED EXPRESSION OF HUMAN LDLR MARKEDLY REDUCES AMYLOID DEPOSITION IN A MOUSE MODEL OF AMYLOID-β AMYLOIDOSIS Alzheimer's & Dementia. 13: P307-P307. DOI: 10.1016/J.Jalz.2017.06.234 |
0.413 |
|
| 2017 |
Vlassenko AG, Gordon BA, Goyal MS, Su Y, Durbin TJ, Couture LE, Holtzman DM, Morris JC, Fagan AM, Benzinger TL, Bateman RJ, Raichle ME. [IC-P-064]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD Alzheimer's & Dementia. 13: P53-P53. DOI: 10.1016/J.Jalz.2017.06.2337 |
0.602 |
|
| 2017 |
Gordon BA, Blazey T, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Fagan AM, Marcus DS, Jack CR, ... ... Holtzman DM, et al. [IC-P-054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK Alzheimer's & Dementia. 13: P44-P45. DOI: 10.1016/J.Jalz.2017.06.2327 |
0.379 |
|
| 2017 |
Babulal GM, Stout SH, Head DM, Holtzman DM, Fagan AM, Morris JC, Roe CM. [P4-185]: NEUROPSYCHIATRIC SYMPTOMS AND ALZHEIMER DISEASE BIOMARKERS PREDICT DRIVING DECLINE Alzheimer's & Dementia. 13: P1335-P1335. DOI: 10.1016/J.Jalz.2017.06.2052 |
0.354 |
|
| 2017 |
Stout SH, Babulal GM, Ma C, Carr DB, Head DM, Grant EA, Williams MM, Holtzman DM, Fagan AM, Morris JC, Roe CM. Driving Cessation Over A 22-Year Period: Dementia Severity And Csf Biomarkers Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.1811 |
0.319 |
|
| 2016 |
Ghosal K, Haag M, Verghese PB, West T, Veenstra T, Braunstein JB, Bateman RJ, Holtzman DM, Landreth GE. A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects. Alzheimer's & Dementia (New York, N. Y.). 2: 110-120. PMID 29067298 DOI: 10.1016/J.Trci.2016.06.001 |
0.804 |
|
| 2016 |
Ju YS, Holtzman DM. Reply to "Do repetitive Valsalva maneuvers reduce glymphatic clearance?" Annals of Neurology. PMID 28019658 DOI: 10.1002/Ana.24849 |
0.512 |
|
| 2016 |
Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takana T, Holtzman DM, Nedergaard M, Deane R. Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Molecular Neurodegeneration. 11: 74. PMID 27931262 DOI: 10.1186/S13024-016-0138-8 |
0.717 |
|
| 2016 |
Musiek ES, Holtzman DM. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science (New York, N.Y.). 354: 1004-1008. PMID 27885006 DOI: 10.1126/Science.Aah4968 |
0.302 |
|
| 2016 |
Stanley M, Macauley SL, Caesar EE, Koscal LJ, Moritz W, Robinson GO, Roh J, Keyser J, Jiang H, Holtzman DM. The Effects of Peripheral and Central High Insulin on Brain Insulin Signaling and Amyloid-β in Young and Old APP/PS1 Mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 11704-11715. PMID 27852778 DOI: 10.1523/Jneurosci.2119-16.2016 |
0.365 |
|
| 2016 |
Deming Y, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Bertelsen S, Huang KL, Sutphen CL, Tarawneh R, Fagan AM, ... Holtzman DM, et al. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. Bmc Neurology. 16: 217. PMID 27832767 DOI: 10.1186/S12883-016-0742-9 |
0.377 |
|
| 2016 |
Baker-Nigh AT, Mawuenyega KG, Bollinger JG, Ovod V, Kasten T, Franklin EE, Liao F, Jiang H, Holtzman D, Cairns NJ, Morris JC, Bateman RJ. Human Central Nervous System (CNS) ApoE Isoforms are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared to Plasma. The Journal of Biological Chemistry. PMID 27793990 DOI: 10.1074/Jbc.M116.721779 |
0.571 |
|
| 2016 |
Morales DM, Silver SA, Morgan CD, Mercer D, Inder TE, Holtzman DM, Wallendorf MJ, Rao R, McAllister JP, Limbrick DD. Lumbar Cerebrospinal Fluid Biomarkers of Posthemorrhagic Hydrocephalus of Prematurity: Amyloid Precursor Protein, Soluble Amyloid Precursor Protein α, and L1 Cell Adhesion Molecule. Neurosurgery. PMID 27571524 DOI: 10.1227/Neu.0000000000001415 |
0.357 |
|
| 2016 |
Chung WS, Verghese PB, Chakraborty C, Joung J, Hyman BT, Ulrich JD, Holtzman DM, Barres BA. Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proceedings of the National Academy of Sciences of the United States of America. PMID 27559087 DOI: 10.1073/Pnas.1609896113 |
0.748 |
|
| 2016 |
Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, Benzinger TL. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. Jama Neurology. PMID 27548756 DOI: 10.1001/Jamaneurol.2016.2642 |
0.492 |
|
| 2016 |
Musiek ES, Xiong DD, Patel T, Sasaki Y, Wang Y, Bauer AQ, Singh R, Finn SL, Culver JP, Milbrandt J, Holtzman DM. Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy. Annals of Clinical and Translational Neurology. 3: 434-42. PMID 27547771 DOI: 10.1002/Acn3.308 |
0.377 |
|
| 2016 |
Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, Maruff P, Snyder PJ, Masters CL, Allegri R, Chhatwal J, Farlow MR, Graff-Radford NR, Laske C, Levin J, ... ... Holtzman DM, et al. BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain : a Journal of Neurology. PMID 27521573 DOI: 10.1093/Brain/Aww200 |
0.576 |
|
| 2016 |
Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, Musch MW, Liao F, Ward JF, Holtzman DM, Chang EB, Tanzi RE, Sisodia SS. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Scientific Reports. 6: 30028. PMID 27443609 DOI: 10.1038/Srep30028 |
0.478 |
|
| 2016 |
Stanley M, Macauley SL, Holtzman DM. Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence? The Journal of Experimental Medicine. PMID 27432942 DOI: 10.1084/Jem.20160493 |
0.427 |
|
| 2016 |
Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TL, Fagan AM, Morris JC, Roe CM. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 27426238 DOI: 10.1016/J.Jagp.2016.04.004 |
0.474 |
|
| 2016 |
Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, Holtzman DM, Benzinger TL, Morris JC, Fagan AM. Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease. Annals of Neurology. PMID 27398953 DOI: 10.1002/Ana.24719 |
0.494 |
|
| 2016 |
Zhao L, Gottesdiener AJ, Parmar M, Li M, Kaminsky SM, Chiuchiolo MJ, Sondhi D, Sullivan PM, Holtzman DM, Crystal RG, Paul SM. Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiology of Aging. 44: 159-172. PMID 27318144 DOI: 10.1016/J.Neurobiolaging.2016.04.020 |
0.535 |
|
| 2016 |
Vos SJ, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, Fagan AM, Benzinger TL. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging. 44: 1-8. PMID 27318129 DOI: 10.1016/J.Neurobiolaging.2016.03.025 |
0.459 |
|
| 2016 |
Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, Aldea P, McConathy J, Holtzman DM, Cairns NJ, Morris JC, Fagan AM, Ances BM, Benzinger TL. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain : a Journal of Neurology. PMID 27286736 DOI: 10.1093/Brain/Aww139 |
0.47 |
|
| 2016 |
Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TL, et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Science Translational Medicine. 8: 338ra66. PMID 27169802 DOI: 10.1126/Scitranslmed.Aaf2362 |
0.522 |
|
| 2016 |
Holtzman DM, Carrillo MC, Hendrix JA, Bain LJ, Catafau AM, Gault LM, Goedert M, Mandelkow E, Mandelkow EM, Miller DS, Ostrowitzki S, Polydoro M, Smith S, Wittmann M, Hutton M. Tau: From research to clinical development. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 27154059 DOI: 10.1016/J.Jalz.2016.03.018 |
0.434 |
|
| 2016 |
Ju YS, Finn MB, Sutphen CL, Herries EM, Jerome GM, Ladenson JH, Crimmins DL, Fagan AM, Holtzman DM. Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid. Annals of Neurology. PMID 27129429 DOI: 10.1002/Ana.24672 |
0.583 |
|
| 2016 |
Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, Fierberg R, Vernon EK, Shulman N, Johnson A, Fague S, Xiong C, Grant EA, Campbell A, Ott BR, ... Holtzman DM, et al. Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Disease and Associated Disorders. PMID 27128959 DOI: 10.1097/Wad.0000000000000154 |
0.474 |
|
| 2016 |
Ingber AP, Hassenstab J, Fagan AM, Benzinger TL, Grant EA, Holtzman DM, Morris JC, Roe CM. Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 27104893 DOI: 10.3233/Jad-150478 |
0.374 |
|
| 2016 |
Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, Grutzendler J, DeMattos RB, Cirrito JR, Holtzman DM, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. The Journal of Experimental Medicine. PMID 27091843 DOI: 10.1084/Jem.20151948 |
0.854 |
|
| 2016 |
Liu CC, Zhao N, Yamaguchi Y, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G. Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease. Science Translational Medicine. 8: 332ra44. PMID 27030596 DOI: 10.1126/Scitranslmed.Aad3650 |
0.746 |
|
| 2016 |
Tarawneh R, D'Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. Jama Neurology. PMID 27018940 DOI: 10.1001/Jamaneurol.2016.0086 |
0.438 |
|
| 2016 |
Lee S, Viqar F, Zimmerman ME, Narkhede A, Tosto G, Benzinger TL, Marcus DS, Fagan AM, Goate A, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, et al. White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the Dominantly Inherited Alzheimer Network. Annals of Neurology. PMID 27016429 DOI: 10.1002/ana.24647 |
0.605 |
|
| 2016 |
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, ... ... Holtzman DM, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 12: 292-323. PMID 27012484 DOI: 10.1016/J.Jalz.2016.02.002 |
0.379 |
|
| 2016 |
Schindler SE, Holtzman DM. CSF sTREM2: marking the tipping point between preclinical AD and dementia? Embo Molecular Medicine. PMID 26976613 DOI: 10.15252/Emmm.201606245 |
0.513 |
|
| 2016 |
Hölttä M, Dean RA, Siemers E, Mawuenyega KG, Sigurdson W, May PC, Holtzman DM, Portelius E, Zetterberg H, Bateman RJ, Blennow K, Gobom J. A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. Alzheimer's Research & Therapy. 8: 11. PMID 26948580 DOI: 10.1186/S13195-016-0178-X |
0.608 |
|
| 2016 |
Simonovitch S, Schmukler E, Bespalko A, Iram T, Frenkel D, Holtzman DM, Masliah E, Michaelson DM, Pinkas-Kramarski R. Impaired Autophagy in APOE4 Astrocytes. Journal of Alzheimer's Disease : Jad. PMID 26923027 DOI: 10.3233/Jad-151101 |
0.526 |
|
| 2016 |
Harris RA, Tindale L, Lone A, Singh O, Macauley SL, Stanley M, Holtzman DM, Bartha R, Cumming RC. Aerobic Glycolysis in the Frontal Cortex Correlates with Memory Performance in Wild-Type Mice But Not the APP/PS1 Mouse Model of Cerebral Amyloidosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 1871-8. PMID 26865611 DOI: 10.1523/Jneurosci.3131-15.2016 |
0.428 |
|
| 2016 |
Ulrich JD, Holtzman DM. TREM2 Function in Alzheimer's disease and neurodegeneration. Acs Chemical Neuroscience. PMID 26854967 DOI: 10.1021/Acschemneuro.5B00313 |
0.547 |
|
| 2016 |
Piccio L, Deming Y, Del-Águila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathologica. PMID 26754641 DOI: 10.1007/S00401-016-1533-5 |
0.337 |
|
| 2016 |
Ghosal K, Haag M, Verghese PB, West T, Veenstra T, Braunstein JB, Bateman RJ, Holtzman DM, Landreth GE. A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2: 110-120. DOI: 10.1016/j.trci.2016.06.001 |
0.803 |
|
| 2016 |
Petros J, Hassenstab J, Snitz BE, Zhou Y, Ringman JM, McDade E, Wang G, Balota DA, Aschenbrenner AJ, Benzinger TL, Cruchaga C, Fagan AM, Goate AM, Holtzman DM, Buckles V, et al. Dynamic Relationships Between “Big Five” Personality Traits, Alzheimer’S Disease Biomarkers, And Cognition In Autosomal Dominant Alzheimer’S Disease Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.970 |
0.492 |
|
| 2016 |
Pankiewicz J, Baquero-Buitrago J, Sanchez S, Lopez-Contreras J, Zaim-Wadghiri Y, Hoang MD, Bard F, Kim J, Sullivan PM, Holtzman DM, Sadowski MJ. Apolipoprotein E Genotype Differentially Modulates Effects Of Anti-Ab Immunotherapy Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.716 |
0.519 |
|
| 2016 |
McDade E, Weng H, Wang G, Xiong C, Fagan AM, Hassenstab J, Marcus DS, Morris JC, Benzinger TL, Cairns NJ, Goate AM, Buckles V, Holtzman DM, Berman S, Ghetti B, et al. O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network Alzheimer's & Dementia. 12: P378-P379. DOI: 10.1016/J.Jalz.2016.06.710 |
0.564 |
|
| 2016 |
Lim YY, Hassenstab J, Cruchaga C, Goate AM, Fagan AM, Lee Smith Benzinger T, Maruff P, Snyder PJ, Masters CL, Ricardo A, Chhatwal JP, Farlow MR, Graff-Radford NR, Laske C, Levin J, ... ... Holtzman DM, et al. F5-02-03: BDNF VAL66MET Moderates Cognitive Impairment, Neuronal Dysfunction and TAU in Preclinical Autosomal Dominant Alzheimer's Disease Alzheimer's & Dementia. 12: P369-P369. DOI: 10.1016/J.Jalz.2016.06.689 |
0.559 |
|
| 2016 |
Deming Y, Harari O, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez V, Budde J, Ma S, Saef B, Bertelsen S, Kauwe J, Fagan AM, Holtzman DM, Morris JC, et al. Cerebrospinal Fluid Levels Of Amyloid Beta And Tau As Endophenotypes Reveal Novel Variants Potentially Informative For Alzheimer'S Disease Alzheimers & Dementia. 12: 252. DOI: 10.1016/J.Jalz.2016.06.452 |
0.458 |
|
| 2016 |
Wang Y, Ulland T, Ulrich JD, Song W, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, DeMattos RB, Grutzendler J, Cirrito JR, Holtzman DM, Colonna M. O2-07-02: Trem2-Mediated Early Response by Resident Microglia Limits Diffusion and Toxicity of Amyloid Plaques Alzheimer's & Dementia. 12: P241-P242. DOI: 10.1016/J.Jalz.2016.06.431 |
0.775 |
|
| 2016 |
Lee S, Zimmerman ME, Viqar F, Narkhede A, Tosto G, Lee Smith Benzinger T, Marcus DS, Goate AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, et al. O2-03-02: are White Matter Hyperintensities a Core Feature of Alzheimer’s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN) Alzheimer's & Dementia. 12: P226-P226. DOI: 10.1016/J.Jalz.2016.06.406 |
0.56 |
|
| 2016 |
Gordon BA, Blazey T, Morris JC, Holtzman DM, Fagan AM, Benzinger TL. O1-07-04: Longitudinal Amyloid Deposition and Hippocampal Volume in Suspected Non-Alzheimer Pathophysiology and Preclinical Alzheimer's Disease Alzheimer's & Dementia. 12: P191-P191. DOI: 10.1016/J.Jalz.2016.06.332 |
0.483 |
|
| 2016 |
Holtzman DM. PL-01-01: Preclinical to Clinical Translation for TAU Therapeutics Alzheimer's & Dementia. 12: P169-P169. DOI: 10.1016/J.Jalz.2016.06.291 |
0.324 |
|
| 2016 |
Ances B, Brier MR, Gordon BA, Friedrichsen KA, McCarthy JE, Stern A, Christensen J, Owen CJ, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, et al. IC-P-179: TAU Imaging Relationships With Amyloid B Imaging, CSF TAU/AB42
, and Cognition in Alzheimer’s Disease Alzheimer's & Dementia. 12: P130-P131. DOI: 10.1016/J.Jalz.2016.06.210 |
0.376 |
|
| 2016 |
Gordon BA, Xiong C, Holtzman DM, Fagan AM, Morris JC, Benzinger TL. IC-P-139: Critical Analysis of Biomarker Cutoffs in Alzheimer Disease Alzheimer's & Dementia. 12: P103-P104. DOI: 10.1016/J.Jalz.2016.06.169 |
0.356 |
|
| 2016 |
Gordon BA, Friedrichsen KA, Brier MR, Blazey T, Su Y, Christensen J, McConathy J, Aldea P, Holtzman DM, Cairns NJ, Morris JC, Fagan AM, Ances B, Benzinger TL. P1-263: Relating PET and CSF Measure of TAU Pathology Alzheimer's & Dementia. 12: P513-P514. DOI: 10.1016/J.Jalz.2016.06.1012 |
0.343 |
|
| 2015 |
Leung YY, Toledo JB, Nefedov A, Polikar R, Raghavan N, Xie SX, Farnum M, Schultz T, Baek Y, Deerlin VV, Hu WT, Holtzman DM, Fagan AM, Perrin RJ, Grossman M, et al. Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimer's & Dementia (Amsterdam, Netherlands). 1: 339-348. PMID 26693175 DOI: 10.1016/J.Dadm.2015.06.008 |
0.696 |
|
| 2015 |
Tambini MD, Pera M, Kanter E, Yang H, Guardia-Laguarta C, Holtzman D, Sulzer D, Area-Gomez E, Schon EA. ApoE4 upregulates the activity of mitochondria-associated ER membranes. Embo Reports. PMID 26564908 DOI: 10.15252/Embr.201540614 |
0.437 |
|
| 2015 |
Moore KM, Girens RE, Larson SK, Jones MR, Restivo JL, Holtzman DM, Cirrito JR, Yuede CM, Zimmerman SD, Timson BF. A spectrum of exercise training reduces soluble Aβ in a dose-dependent manner in a mouse model of Alzheimer's disease. Neurobiology of Disease. PMID 26563933 DOI: 10.1016/J.Nbd.2015.11.004 |
0.63 |
|
| 2015 |
Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, Holtzman DM. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathologica Communications. 3: 70. PMID 26556230 DOI: 10.1186/S40478-015-0250-Y |
0.51 |
|
| 2015 |
Kim J, Yoon H, Horie T, Burchett JM, Restivo JL, Rotllan N, Ramírez CM, Verghese PB, Ihara M, Hoe HS, Esau C, Fernández-Hernando C, Holtzman DM, Cirrito JR, Ono K, et al. microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 14717-26. PMID 26538644 DOI: 10.1523/Jneurosci.2053-15.2015 |
0.837 |
|
| 2015 |
Yamada K, Patel TK, Hochgräfe K, Mahan TE, Jiang H, Stewart FR, Mandelkow EM, Holtzman DM. Analysis of in vivo turnover of tau in a mouse model of tauopathy. Molecular Neurodegeneration. 10: 55. PMID 26502977 DOI: 10.1186/S13024-015-0052-5 |
0.805 |
|
| 2015 |
Ulrich JD, Huynh TP, Holtzman DM. Re-evaluation of the Blood-Brain Barrier in the Presence of Alzheimer's Disease Pathology. Neuron. 88: 237-9. PMID 26494271 DOI: 10.1016/J.Neuron.2015.10.008 |
0.386 |
|
| 2015 |
Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimer's Research & Therapy. 7: 59. PMID 26383836 DOI: 10.1186/S13195-015-0142-1 |
0.341 |
|
| 2015 |
Zhu L, Zhong M, Elder GA, Sano M, Holtzman DM, Gandy S, Cardozo C, Haroutunian V, Robakis NK, Cai D. Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 112: 11965-70. PMID 26372964 DOI: 10.1073/Pnas.1510011112 |
0.516 |
|
| 2015 |
Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. Jama Neurology. 1-7. PMID 26366630 DOI: 10.1001/Jamaneurol.2015.1867 |
0.342 |
|
| 2015 |
Ising C, Stanley M, Holtzman DM. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development. Clinical Pharmacology and Therapeutics. 98: 469-71. PMID 26250900 DOI: 10.1002/Cpt.200 |
0.55 |
|
| 2015 |
Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, et al. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. Jama Neurology. 72: 1029-1042. PMID 26147946 DOI: 10.1001/Jamaneurol.2015.1285 |
0.466 |
|
| 2015 |
Macauley SL, Holtzman DM. Recent Advances from the Bench Toward the Bedside in Alzheimer's Disease. Ebiomedicine. 2: 94-5. PMID 26137544 DOI: 10.1016/J.Ebiom.2015.01.002 |
0.529 |
|
| 2015 |
Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI. Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake. The Journal of Biological Chemistry. 290: 21652-62. PMID 26126828 DOI: 10.1074/Jbc.M115.657924 |
0.437 |
|
| 2015 |
Lucey BP, Holtzman DM. How amyloid, sleep and memory connect. Nature Neuroscience. 18: 933-4. PMID 26108720 DOI: 10.1038/Nn.4048 |
0.331 |
|
| 2015 |
Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, Xiong C, Chott R, Yarasheski K, Sigurdson W, Zhang L, Goate A, Benzinger T, Morris JC, Holtzman D, et al. Age and amyloid effects on human CNS amyloid-beta kinetics. Annals of Neurology. PMID 26040676 DOI: 10.1002/Ana.24454 |
0.598 |
|
| 2015 |
Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nature Neuroscience. 18: 800-6. PMID 26007213 DOI: 10.1038/Nn.4018 |
0.519 |
|
| 2015 |
Yan P, Zhu A, Liao F, Xiao Q, Kraft AW, Gonzales E, Perez R, Greenberg SM, Holtzman DM, Lee JM. Minocycline reduces spontaneous hemorrhage in mouse models of cerebral amyloid angiopathy. Stroke; a Journal of Cerebral Circulation. 46: 1633-40. PMID 25944329 DOI: 10.1161/Strokeaha.115.008582 |
0.376 |
|
| 2015 |
Macauley SL, Stanley M, Caesar EE, Yamada SA, Raichle ME, Perez R, Mahan TE, Sutphen CL, Holtzman DM. Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo. The Journal of Clinical Investigation. 125: 2463-7. PMID 25938784 DOI: 10.1172/Jci79742 |
0.797 |
|
| 2015 |
Yamamoto K, Tanei Z, Hashimoto T, Wakabayashi T, Okuno H, Naka Y, Yizhar O, Fenno LE, Fukayama M, Bito H, Cirrito JR, Holtzman DM, Deisseroth K, Iwatsubo T. Chronic optogenetic activation augments aβ pathology in a mouse model of Alzheimer disease. Cell Reports. 11: 859-65. PMID 25937280 DOI: 10.1016/J.Celrep.2015.04.017 |
0.686 |
|
| 2015 |
Liao F, Jiang H, Srivatsan S, Xiao Q, Lefton KB, Yamada K, Mahan TE, Lee JM, Shaw AS, Holtzman DM. Effects of CD2-associated protein deficiency on amyloid-β in neuroblastoma cells and in an APP transgenic mouse model. Molecular Neurodegeneration. 10: 12. PMID 25887956 DOI: 10.1186/S13024-015-0006-Y |
0.809 |
|
| 2015 |
Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. Jama Neurology. 72: 656-65. PMID 25867677 DOI: 10.1001/Jamaneurol.2015.0202 |
0.437 |
|
| 2015 |
Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Annals of Clinical and Translational Neurology. 2: 278-88. PMID 25815354 DOI: 10.1002/Acn3.176 |
0.823 |
|
| 2015 |
Sahlholm K, Liao F, Holtzman DM, Xu J, Mach RH. Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice. Biochemical and Biophysical Research Communications. 460: 439-45. PMID 25796326 DOI: 10.1016/J.Bbrc.2015.03.052 |
0.445 |
|
| 2015 |
Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Experimental & Molecular Medicine. 47: e148. PMID 25766617 DOI: 10.1038/Emm.2014.121 |
0.376 |
|
| 2015 |
Morales DM, Holubkov R, Inder TE, Ahn HC, Mercer D, Rao R, McAllister JP, Holtzman DM, Limbrick DD. Cerebrospinal fluid levels of amyloid precursor protein are associated with ventricular size in post-hemorrhagic hydrocephalus of prematurity. Plos One. 10: e0115045. PMID 25738507 DOI: 10.1371/Journal.Pone.0115045 |
0.329 |
|
| 2015 |
Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 160: 1061-71. PMID 25728668 DOI: 10.1016/J.Cell.2015.01.049 |
0.695 |
|
| 2015 |
Gordon BA, Zacks JM, Blazey T, Benzinger TL, Morris JC, Fagan AM, Holtzman DM, Balota DA. Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. Neurobiology of Aging. 36: 1771-9. PMID 25708908 DOI: 10.1016/J.Neurobiolaging.2015.01.019 |
0.406 |
|
| 2015 |
Han BH, Zhou ML, Johnson AW, Singh I, Liao F, Vellimana AK, Nelson JW, Milner E, Cirrito JR, Basak J, Yoo M, Dietrich HH, Holtzman DM, Zipfel GJ. Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice. Proceedings of the National Academy of Sciences of the United States of America. 112: E881-90. PMID 25675483 DOI: 10.1073/Pnas.1414930112 |
0.825 |
|
| 2015 |
Hyman BT, Holtzman DM. Apolipoprotein E levels and Alzheimer risk. Annals of Neurology. 77: 204-5. PMID 25583643 DOI: 10.1002/Ana.24355 |
0.358 |
|
| 2015 |
Aschenbrenner AJ, Balota DA, Tse CS, Fagan AM, Holtzman DM, Benzinger TL, Morris JC. Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. Neuropsychology. 29: 368-81. PMID 25222200 DOI: 10.1037/Neu0000133 |
0.424 |
|
| 2015 |
Liao F, Zhang TJ, Mahan TE, Jiang H, Holtzman DM. Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid-β in an APP transgenic mouse model. Brain, Behavior, and Immunity. 47: 163-71. PMID 25218899 DOI: 10.1016/J.Bbi.2014.09.005 |
0.801 |
|
| 2015 |
Roh JH, Jiang H, Finn MB, Stewart FR, Mahan TE, Cirrito JR, Heda A, Joy Snider B, Li M, Yanagisawa M, de Lecea L, Holtzman DM. Correction to Potential role of orexin and sleep modulation in the pathogenesis of alzheimer's disease [The Journal of Experimental Medicine, 211, 13, (2014), 2487-2496] Journal of Experimental Medicine. 212: 121. DOI: 10.1084/Jem.2014178812122014C |
0.623 |
|
| 2015 |
Ooms S, Zempel J, Holtzman D, Ju Y. Automated slow wave sleep disruption in middle-aged adults Sleep Medicine. 16: S16. DOI: 10.1016/J.Sleep.2015.02.037 |
0.501 |
|
| 2015 |
Kester MI, Teunissen CE, Crimmins DL, Macy EM, Ladenson JH, Scheltens P, Flier WMvd, Morris JC, Holtzman DM, Fagan AM. Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease Alzheimers & Dementia. 11: 326. DOI: 10.1016/J.Jalz.2015.07.471 |
0.417 |
|
| 2015 |
Perrin RJ, Weng H, Bales KR, Morris JC, Benzinger TL, Fagan AM, Xiong C, Holtzman DM. O3-14-03: Novel fluid biomarkers for brain amyloid and dementia risk in presymptomatic Alzheimer disease Alzheimer's & Dementia. 11: P255-P255. DOI: 10.1016/J.Jalz.2015.07.317 |
0.673 |
|
| 2015 |
Holtzman DM. F2-02-02: Effects of disrupted sleep on abeta and tau pathology and effects of abeta and tau pathology on sleep: A vicious cycle? Alzheimer's & Dementia. 11: P165-P166. DOI: 10.1016/J.Jalz.2015.07.113 |
0.352 |
|
| 2015 |
Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, Fierberg R, Vernon EK, Shulman N, Johnson A, Fague MS, Xiong C, Grant E, Campbell A, Holtzman DM, et al. P2-130: Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease Alzheimer's & Dementia. 11: P533-P534. DOI: 10.1016/J.Jalz.2015.06.668 |
0.424 |
|
| 2015 |
Huff MJ, Balota DA, Aschenbrenner AJ, Duchek JM, Fagan AM, Holtzman DM, Benzinger TL, Morris JC. P2-085: Task-switching errors show sensitivity to preclinical Alzheimer's disease biomarkers Alzheimer's & Dementia. 11: P516-P516. DOI: 10.1016/J.Jalz.2015.06.622 |
0.336 |
|
| 2015 |
Gordon BA, Vos S, Morris JC, Holtzman DM, Fagan AM, Benzinger TL. IC-P-020: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers Alzheimer's & Dementia. 11: P24-P25. DOI: 10.1016/J.Jalz.2015.06.040 |
0.366 |
|
| 2015 |
Leung YY, Toledo JB, Nefedov A, Polikar R, Raghavan N, Xie SX, Farnum M, Schultz T, Baek Y, Deerlin VV, Hu WT, Holtzman DM, Fagan AM, Perrin RJ, Grossman M, et al. Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 1: 339-348. DOI: 10.1016/j.dadm.2015.06.008 |
0.644 |
|
| 2014 |
Roh JH, Jiang H, Finn MB, Stewart FR, Mahan TE, Cirrito JR, Heda A, Snider BJ, Li M, Yanagisawa M, de Lecea L, Holtzman DM. Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease. The Journal of Experimental Medicine. 211: 2487-96. PMID 25422493 DOI: 10.1084/Jem.20141788 |
0.811 |
|
| 2014 |
Lim MM, Gerstner JR, Holtzman DM. The sleep-wake cycle and Alzheimer's disease: what do we know? Neurodegenerative Disease Management. 4: 351-62. PMID 25405649 DOI: 10.2217/Nmt.14.33 |
0.629 |
|
| 2014 |
Kauwe JS, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL, Staley LA, Karch CM, Harari O, Cruchaga C, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, ... ... Holtzman DM, et al. Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. Plos Genetics. 10: e1004758. PMID 25340798 DOI: 10.1371/Journal.Pgen.1004758 |
0.343 |
|
| 2014 |
Dikranian K, Holtzman DM. The Ultrastructural Identity of Alzheimer's Pathology: Lessons from Animal Models. Journal of Neurological Disorders. 2: e111. PMID 25309943 DOI: 10.4172/2329-6895.1000E111 |
0.516 |
|
| 2014 |
Liao F, Holtzman DM. Human neurons derived from induced pluripotent stem cells as a new platform for preclinical drug screening and development. Jama Neurology. 71: 1475-6. PMID 25285675 DOI: 10.1001/Jamaneurol.2014.2802 |
0.494 |
|
| 2014 |
Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM, Diamond MI. Proteopathic tau seeding predicts tauopathy in vivo. Proceedings of the National Academy of Sciences of the United States of America. 111: E4376-85. PMID 25261551 DOI: 10.1073/Pnas.1411649111 |
0.799 |
|
| 2014 |
Garai K, Verghese PB, Baban B, Holtzman DM, Frieden C. The binding of apolipoprotein E to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation. Biochemistry. 53: 6323-31. PMID 25207746 DOI: 10.1021/Bi5008172 |
0.774 |
|
| 2014 |
Milner E, Zhou ML, Johnson AW, Vellimana AK, Greenberg JK, Holtzman DM, Han BH, Zipfel GJ. Cerebral amyloid angiopathy increases susceptibility to infarction after focal cerebral ischemia in Tg2576 mice. Stroke; a Journal of Cerebral Circulation. 45: 3064-9. PMID 25190447 DOI: 10.1161/Strokeaha.114.006078 |
0.44 |
|
| 2014 |
Thomas JB, Brier MR, Bateman RJ, Snyder AZ, Benzinger TL, Xiong C, Raichle M, Holtzman DM, Sperling RA, Mayeux R, Ghetti B, Ringman JM, Salloway S, McDade E, Rossor MN, et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease. Jama Neurology. 71: 1111-22. PMID 25069482 DOI: 10.1001/Jamaneurol.2014.1654 |
0.569 |
|
| 2014 |
Pankiewicz JE, Guridi M, Kim J, Asuni AA, Sanchez S, Sullivan PM, Holtzman DM, Sadowski MJ. Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice. Acta Neuropathologica Communications. 2: 75. PMID 24972680 DOI: 10.1186/Preaccept-1147957959132865 |
0.712 |
|
| 2014 |
Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM. Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2. Molecular Neurodegeneration. 9: 20. PMID 24893973 DOI: 10.1186/1750-1326-9-20 |
0.808 |
|
| 2014 |
Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, Culver JP, Betensky R, Wozniak DF, Hyman BT, Holtzman DM. Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 7281-92. PMID 24849360 DOI: 10.1523/Jneurosci.0646-14.2014 |
0.855 |
|
| 2014 |
Shin S, Walz KA, Archambault AS, Sim J, Bollman BP, Koenigsknecht-Talboo J, Cross AH, Holtzman DM, Wu GF. Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis. Journal of Neuroimmunology. 271: 8-17. PMID 24794230 DOI: 10.1016/J.Jneuroim.2014.03.010 |
0.363 |
|
| 2014 |
Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, ... ... Holtzman DM, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Science Translational Medicine. 6: 226ra30. PMID 24598588 DOI: 10.1126/Scitranslmed.3007901 |
0.635 |
|
| 2014 |
Harari O, Cruchaga C, Kauwe JS, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Goate AM. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Biological Psychiatry. 75: 723-31. PMID 24548642 DOI: 10.1016/J.Biopsych.2013.11.032 |
0.445 |
|
| 2014 |
Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgräfe K, Mandelkow EM, Holtzman DM. Neuronal activity regulates extracellular tau in vivo. The Journal of Experimental Medicine. 211: 387-93. PMID 24534188 DOI: 10.1085/Jgp.1434Oia12 |
0.808 |
|
| 2014 |
Caglayan S, Takagi-Niidome S, Liao F, Carlo AS, Schmidt V, Burgert T, Kitago Y, Füchtbauer EM, Füchtbauer A, Holtzman DM, Takagi J, Willnow TE. Lysosomal sorting of amyloid-β by the SORLA receptor is impaired by a familial Alzheimer's disease mutation. Science Translational Medicine. 6: 223ra20. PMID 24523320 DOI: 10.1126/Scitranslmed.3007747 |
0.514 |
|
| 2014 |
Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D, Sims R, Lambert JC, Gibbs JR, Bras J, Sassi C, Harari O, Bertelsen S, Lupton MK, Powell J, ... ... Holtzman DM, et al. Missense variant in TREML2 protects against Alzheimer's disease. Neurobiology of Aging. 35: 1510.e19-26. PMID 24439484 DOI: 10.1016/J.Neurobiolaging.2013.12.010 |
0.429 |
|
| 2014 |
Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology--a bidirectional relationship. Nature Reviews. Neurology. 10: 115-9. PMID 24366271 DOI: 10.1038/Nrneurol.2013.269 |
0.4 |
|
| 2014 |
Brier MR, Thomas JB, Fagan AM, Hassenstab J, Holtzman DM, Benzinger TL, Morris JC, Ances BM. Functional connectivity and graph theory in preclinical Alzheimer's disease. Neurobiology of Aging. 35: 757-68. PMID 24216223 DOI: 10.1016/J.Neurobiolaging.2013.10.081 |
0.469 |
|
| 2014 |
Sutphen CL, Fagan AM, Holtzman DM. Progress update: fluid and imaging biomarkers in Alzheimer's disease. Biological Psychiatry. 75: 520-6. PMID 24012326 DOI: 10.1016/J.Biopsych.2013.07.031 |
0.444 |
|
| 2014 |
Pankiewicz JE, Guridi M, Kim J, Asuni AA, Sanchez S, Sullivan PM, Holtzman DM, Sadowski MJ. Blocking the apoE/Aß interaction ameliorates Aß-related pathology in APOE ¿2 and ¿4 targeted replacement Alzheimer model mice Acta Neuropathologica Communications. 2: 75. DOI: 10.1186/PREACCEPT-1147957959132865 |
0.328 |
|
| 2014 |
Sutphen CL, Shah AR, Jasielec M, Xiong C, Vlassenko AG, Benzinger T, Stoops E, Vanderstichele H, Brix B, Darby H, Leen Jef Vandijck M, Ladenson JH, Holtzman D, Morris JC, Fagan AM. P1-143: LONGITUDINAL CHANGES IN CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE: FINDINGS FROM A COGNITIVELY NORMAL, MIDDLE-AGED COHORT Alzheimer's & Dementia. 10: P352-P353. DOI: 10.1016/J.Jalz.2014.05.380 |
0.354 |
|
| 2014 |
Aschenbrenner AJ, Balota DA, Tse C, Fagan AM, Holtzman DM, Benzinger TL, Morris JC. P1-021: SYNERGISTIC AND MEDIATIONAL EFFECTS OF ALZHEIMER'S DISEASE BIOMARKERS ON A COGNITIVE MEASURE Alzheimer's & Dementia. 10: P311-P312. DOI: 10.1016/J.Jalz.2014.05.256 |
0.373 |
|
| 2014 |
Vlassenko AG, Fagan AM, Jasielec MS, Su Y, Xiong C, Holtzman DM, Benzinger TL, Morris JC. IC-P-008: REGIONAL PIB DEPOSITION AND CSF Aβ42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY Alzheimer's & Dementia. 10: P11-P11. DOI: 10.1016/J.Jalz.2014.05.012 |
0.396 |
|
| 2013 |
Jack CR, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron. 80: 1347-58. PMID 24360540 DOI: 10.1016/J.Neuron.2013.12.003 |
0.488 |
|
| 2013 |
Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Shinohara M, Holtzman DM, Bu G. Neuronal clearance of amyloid-β by endocytic receptor LRP1. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 19276-83. PMID 24305823 DOI: 10.1523/Jneurosci.3487-13.2013 |
0.709 |
|
| 2013 |
Musiek ES, Lim MM, Yang G, Bauer AQ, Qi L, Lee Y, Roh JH, Ortiz-Gonzalez X, Dearborn JT, Culver JP, Herzog ED, Hogenesch JB, Wozniak DF, Dikranian K, Giasson BI, ... ... Holtzman DM, et al. Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. The Journal of Clinical Investigation. 123: 5389-400. PMID 24270424 DOI: 10.1172/Jci70317 |
0.755 |
|
| 2013 |
Roe CM, Fagan AM, Grant EA, Holtzman DM, Morris JC. CSF biomarkers of Alzheimer disease: "noncognitive" outcomes. Neurology. 81: 2028-31. PMID 24212387 DOI: 10.1212/01.Wnl.0000436940.78152.05 |
0.401 |
|
| 2013 |
Lehtinen MK, Bjornsson CS, Dymecki SM, Gilbertson RJ, Holtzman DM, Monuki ES. The choroid plexus and cerebrospinal fluid: emerging roles in development, disease, and therapy. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 17553-9. PMID 24198345 DOI: 10.1523/Jneurosci.3258-13.2013 |
0.307 |
|
| 2013 |
Benzinger TL, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, ... ... Holtzman DM, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 110: E4502-9. PMID 24194552 DOI: 10.1073/Pnas.1317918110 |
0.542 |
|
| 2013 |
Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 80: 402-14. PMID 24075978 DOI: 10.1016/J.Neuron.2013.07.046 |
0.834 |
|
| 2013 |
Duchek JM, Balota DA, Thomas JB, Snyder AZ, Rich P, Benzinger TL, Fagan AM, Holtzman DM, Morris JC, Ances BM. Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults. Neuropsychology. 27: 516-28. PMID 24040929 DOI: 10.1037/A0033402 |
0.366 |
|
| 2013 |
Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. The Lancet. Neurology. 12: 957-65. PMID 24012374 DOI: 10.1016/S1474-4422(13)70194-7 |
0.44 |
|
| 2013 |
Benitez BA, Karch CM, Cai Y, Jin SC, Cooper B, Carrell D, Bertelsen S, Chibnik L, Schneider JA, Bennett DA, Fagan AM, Holtzman D, Morris JC, et al. The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers. Plos Genetics. 9: e1003685. PMID 23990795 DOI: 10.1371/Journal.Pgen.1003685 |
0.403 |
|
| 2013 |
Wang L, Brier MR, Snyder AZ, Thomas JB, Fagan AM, Xiong C, Benzinger TL, Holtzman DM, Morris JC, Ances BM. Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. Jama Neurology. 70: 1242-8. PMID 23959173 DOI: 10.1001/Jamaneurol.2013.3253 |
0.355 |
|
| 2013 |
Ju YE, Holtzman DM. Sleep evaluation by actigraphy for patients with Alzheimer disease--reply. Jama Neurology. 70: 1074-5. PMID 23939592 DOI: 10.1001/Jamaneurol.2013.3490 |
0.326 |
|
| 2013 |
DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, Schuler DR, Maloney SE, Wozniak DF, Rigo F, Bennett CF, Cirrito JR, Holtzman DM, Miller TM. Antisense reduction of tau in adult mice protects against seizures. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 12887-97. PMID 23904623 DOI: 10.1523/Jneurosci.2107-13.2013 |
0.737 |
|
| 2013 |
Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, Bateman RJ. Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Science Translational Medicine. 5: 189ra77. PMID 23761040 DOI: 10.1126/Scitranslmed.3005615 |
0.583 |
|
| 2013 |
Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science (New York, N.Y.). 340: 924-f. PMID 23704555 DOI: 10.1126/Science.1235505 |
0.487 |
|
| 2013 |
Perrin RJ, Payton JE, Malone JP, Gilmore P, Davis AE, Xiong C, Fagan AM, Townsend RR, Holtzman DM. Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation. Plos One. 8: e64314. PMID 23700471 DOI: 10.1371/Journal.Pone.0064314 |
0.517 |
|
| 2013 |
Zhang YH, Raymick J, Sarkar S, Lahiri DK, Ray B, Holtzman D, Dumas M, Schmued LC. Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease. Current Alzheimer Research. 10: 494-506. PMID 23627708 DOI: 10.2174/1567205011310050005 |
0.523 |
|
| 2013 |
Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proceedings of the National Academy of Sciences of the United States of America. 110: E1807-16. PMID 23620513 DOI: 10.1073/Pnas.1220484110 |
0.824 |
|
| 2013 |
Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Molecular Neurodegeneration. 8: 13. PMID 23601557 DOI: 10.1186/1750-1326-8-13 |
0.833 |
|
| 2013 |
Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, ... ... Holtzman DM, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron. 78: 256-68. PMID 23562540 DOI: 10.1016/J.Neuron.2013.02.026 |
0.429 |
|
| 2013 |
Kuszczyk MA, Sanchez S, Pankiewicz J, Kim J, Duszczyk M, Guridi M, Asuni AA, Sullivan PM, Holtzman DM, Sadowski MJ. Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration. The American Journal of Pathology. 182: 1750-68. PMID 23499462 DOI: 10.1016/J.Ajpath.2013.01.034 |
0.65 |
|
| 2013 |
Ju YE, McLeland JS, Toedebusch CD, Xiong C, Fagan AM, Duntley SP, Morris JC, Holtzman DM. Sleep quality and preclinical Alzheimer disease. Jama Neurology. 70: 587-93. PMID 23479184 DOI: 10.1001/Jamaneurol.2013.2334 |
0.352 |
|
| 2013 |
Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL. Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Annals of Neurology. 73: 104-19. PMID 23225543 DOI: 10.1002/Ana.23748 |
0.754 |
|
| 2013 |
Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, Holtzman DM, Wancewicz E, Bennett CF, Bowser R, Cudkowicz M, Miller TM. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. Jama Neurology. 70: 201-7. PMID 23147550 DOI: 10.1001/Jamaneurol.2013.593 |
0.368 |
|
| 2013 |
Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, Gil SC, Brown J, Wilhelmsson U, Restivo JL, Cirrito JR, Holtzman DM, Kim J, Pekny M, Lee JM. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 187-98. PMID 23038755 DOI: 10.1096/Fj.12-208660 |
0.829 |
|
| 2013 |
Yanamandra K, Kfoury N, Jiang H, Mahan T, Ma S, Maloney S, Wozniak D, Diamond MI, Holtzman D. Erratum to Anti-Tau antibodies that block tau aggregate seeding invitro markedly decrease pathology and improve cognition in vivo [Neuron, 74, (2012), 227-245] Neuron. 80. DOI: 10.1016/J.Neuron.2013.12.007 |
0.37 |
|
| 2013 |
Wang L, Brier M, Snyder A, Thomas J, Fagan A, Xiong C, Benzinger T, Holtzman D, Morris J, Ances B. P2-159: Cerebrospinal fluid beta-amyloid 42, tau, phosphorylated tau 181, and resting state functional connectivity Alzheimer's & Dementia. 9: P405-P406. DOI: 10.1016/J.Jalz.2013.05.804 |
0.39 |
|
| 2013 |
Shah A, Sutphen C, Amos M, Althage M, Morris J, Holtzman D, Fagan A. Evaluation of pre-analytical and analytical factors that contribute to variability in CSF biomarker levels Alzheimers & Dementia. 9: 211. DOI: 10.1016/J.Jalz.2013.05.393 |
0.337 |
|
| 2013 |
Cruchaga C, Harari O, Kauwe J, Bales K, Pickering EH, Bertelsen S, Fagan A, Holtzman D, Morris J, Goate A. P4-002: Cerebrospinal heart fatty-acid-binding protein as a biomarker for Alzheimer's disease Alzheimer's & Dementia. 9: P705-P705. DOI: 10.1016/J.Jalz.2013.05.1390 |
0.343 |
|
| 2013 |
Wang L, Brier M, Snyder A, Thomas J, Fagan A, Xiong C, Benzinger T, Holtzman D, Morris J, Ances B. IC-P-113: Cerebrospinal fluid beta-amyloid 42, tau, ptau181 and resting state functional connectivity Alzheimer's & Dementia. 9: P68-P69. DOI: 10.1016/J.Jalz.2013.05.110 |
0.352 |
|
| 2013 |
Brier M, Thomas J, Fagan A, Holtzman D, Benzinger T, Morris J, Ances B. IC-P-085: Early pathological changes due to Alzheimer's disease are detected by graph theoretical measures of functional connectivity Alzheimer's & Dementia. 9: P50-P50. DOI: 10.1016/J.Jalz.2013.05.082 |
0.337 |
|
| 2013 |
Vos S, Xiong C, Grant E, Visser PJ, Cairns N, Morris J, Holtzman D, Fagan A. O4-02-03: Using cerebrospinal fluid markers to identify stages of National Institute on Aging and Alzheimer's Association proposed criteria for preclinical Alzheimer's disease and its prognosis Alzheimer's & Dementia. 9: P682-P682. DOI: 10.1016/J.Jalz.2013.04.342 |
0.393 |
|
| 2013 |
Benitez B, Karch C, Jin SC, Carrel D, Cooper B, Bertelsen S, Morris J, Holtzman D, Goate A, Cruchaga C. Rare variants in APP and PSEN1 genes associated with extreme levels of beta-amyloid 42 and tau protein in cerebrospinal fluid Alzheimers & Dementia. 9: 680. DOI: 10.1016/J.Jalz.2013.04.338 |
0.397 |
|
| 2013 |
Roh JH, Heda A, Finn MB, Mahan T, Li M, Nishino S, Holtzman D. Potential role of orexin in the pathogenesis of Alzheimer's disease Alzheimers & Dementia. 9: 521. DOI: 10.1016/J.Jalz.2013.04.246 |
0.418 |
|
| 2013 |
Pankiewicz J, Kim J, Ormazabal MG, Sanchez S, Granovetter M, Sullivan P, Holtzman D, Sadowski M. O1-11-05: Pharmacological inhibition of the beta-amyloid and apolipoprotein E interaction ameliorates Alzheimer's pathology in APPSW/PS1dE9 / APOE-ε2-TR and APPSW/PS1dE9 / APOE-ε4-TR mice Alzheimer's & Dementia. 9: P152-P153. DOI: 10.1016/J.Jalz.2013.04.114 |
0.658 |
|
| 2013 |
Leung YY, Toledo J, Nefedov A, Polikar R, Raghavan N, Xie S, Farnum M, Schultz T, Baek Y, Lobanov V, DiBernardo A, Deerlin VV, Kling M, Chen-Plotkin A, Mailman M, ... ... Holtzman D, et al. Identifying multi-analyte CSF biomarkers for Alzheimer’s disease in a multi-cohort study Alzheimers & Dementia. 9. DOI: 10.1016/J.Jalz.2013.04.059 |
0.583 |
|
| 2012 |
Roh JH, Holtzman DM. Stealth attack: plaque-specific antibody allows for efficient Aβ removal without side effects. Neuron. 76: 859-61. PMID 23217733 DOI: 10.1016/J.Neuron.2012.11.018 |
0.417 |
|
| 2012 |
Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clinical Investigation. 2: 975-984. PMID 23139856 DOI: 10.4155/Cli.12.93 |
0.537 |
|
| 2012 |
Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis. The Journal of Experimental Medicine. 209: 2149-56. PMID 23129750 DOI: 10.1084/Jem.20121274 |
0.84 |
|
| 2012 |
Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer disease in 2020. Cold Spring Harbor Perspectives in Medicine. 2. PMID 23125202 DOI: 10.1101/Cshperspect.A011585 |
0.406 |
|
| 2012 |
Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, Frosch MP, Spires-Jones TL, Finn MB, Holtzman DM, Hyman BT. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 15181-92. PMID 23100439 DOI: 10.1523/Jneurosci.1542-12.2012 |
0.533 |
|
| 2012 |
Musiek ES, Holtzman DM. Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Current Opinion in Neurology. 25: 715-20. PMID 23041958 DOI: 10.1097/Wco.0B013E32835A30F4 |
0.506 |
|
| 2012 |
Xiao Q, Ford AL, Xu J, Yan P, Lee KY, Gonzales E, West T, Holtzman DM, Lee JM. Bcl-x pre-mRNA splicing regulates brain injury after neonatal hypoxia-ischemia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 13587-96. PMID 23015448 DOI: 10.1523/Jneurosci.2617-12.2012 |
0.506 |
|
| 2012 |
Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM. Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Science Translational Medicine. 4: 150ra122. PMID 22956200 DOI: 10.1126/Scitranslmed.3004291 |
0.815 |
|
| 2012 |
Dikranian K, Kim J, Stewart FR, Levy MA, Holtzman DM. Ultrastructural studies in APP/PS1 mice expressing human ApoE isoforms: implications for Alzheimer's disease. International Journal of Clinical and Experimental Pathology. 5: 482-95. PMID 22949930 |
0.684 |
|
| 2012 |
Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proceedings of the National Academy of Sciences of the United States of America. 109: 15502-7. PMID 22927427 DOI: 10.1073/Pnas.1206446109 |
0.822 |
|
| 2012 |
Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 79: 897-905. PMID 22855860 DOI: 10.1212/Wnl.0B013E318266Fa70 |
0.823 |
|
| 2012 |
Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, Bertelsen S, Hinrichs A, Fagan AM, Holtzman DM, Morris JC, Goate AM. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Human Molecular Genetics. 21: 4558-71. PMID 22821396 DOI: 10.1093/Hmg/Dds296 |
0.405 |
|
| 2012 |
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. The New England Journal of Medicine. 367: 795-804. PMID 22784036 DOI: 10.1056/Nejmoa1202753 |
0.581 |
|
| 2012 |
Brier MR, Thomas JB, Snyder AZ, Benzinger TL, Zhang D, Raichle ME, Holtzman DM, Morris JC, Ances BM. Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 8890-9. PMID 22745490 DOI: 10.1523/Jneurosci.5698-11.2012 |
0.436 |
|
| 2012 |
Hunter JM, Cirrito JR, Restivo JL, Kinley RD, Sullivan PM, Holtzman DM, Koger D, Delong C, Lin S, Zhao L, Liu F, Bales K, Paul SM. Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. Brain Research. 1467: 120-32. PMID 22682924 DOI: 10.1016/J.Brainres.2012.05.048 |
0.633 |
|
| 2012 |
Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim J, Yarasheski KE, Wang JX, Mawuenyega KG, Jiang H, Parsadanian M, Yoon H, Kasten T, Sigurdson WC, Xiong C, Goate A, ... Holtzman DM, et al. In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. Plos One. 7: e38013. PMID 22675504 DOI: 10.1371/Journal.Pone.0038013 |
0.846 |
|
| 2012 |
Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, Hou S, Kopeikina KJ, Frosch MP, Lee VM, Holtzman DM, Hyman BT, Spires-Jones TL. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain : a Journal of Neurology. 135: 2155-68. PMID 22637583 DOI: 10.1093/Brain/Aws127 |
0.483 |
|
| 2012 |
Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 485: 512-6. PMID 22622580 DOI: 10.1038/Nature11087 |
0.452 |
|
| 2012 |
Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harbor Perspectives in Medicine. 2: a006148. PMID 22553492 DOI: 10.1101/Cshperspect.A006148 |
0.414 |
|
| 2012 |
Hata S, Taniguchi M, Piao Y, Ikeuchi T, Fagan AM, Holtzman DM, Bateman R, Sohrabi HR, Martins RN, Gandy S, Urakami K, Suzuki T. Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects. Molecular Neurodegeneration. 7: 16. PMID 22534039 DOI: 10.1186/1750-1326-7-16 |
0.576 |
|
| 2012 |
Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ. Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 31: 335-41. PMID 22531418 DOI: 10.3233/Jad-2012-120508 |
0.575 |
|
| 2012 |
Holtzman DM. CSF biomarkers for secondary prevention trials: why markers of amyloid deposition and neurodegeneration are both important. Archives of Neurology. 69: 691-2. PMID 22529246 DOI: 10.1001/Archneurol.2012.587 |
0.399 |
|
| 2012 |
Basak JM, Kim J, Pyatkivskyy Y, Wildsmith KR, Jiang H, Parsadanian M, Patterson BW, Bateman RJ, Holtzman DM. Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling. Molecular Neurodegeneration. 7: 14. PMID 22512932 DOI: 10.1186/1750-1326-7-14 |
0.828 |
|
| 2012 |
Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. The Journal of Biological Chemistry. 287: 19440-51. PMID 22461630 DOI: 10.1074/Jbc.M112.346072 |
0.434 |
|
| 2012 |
Bero AW, Bauer AQ, Stewart FR, White BR, Cirrito JR, Raichle ME, Culver JP, Holtzman DM. Bidirectional relationship between functional connectivity and amyloid-β deposition in mouse brain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 4334-40. PMID 22457485 DOI: 10.1523/Jneurosci.5845-11.2012 |
0.831 |
|
| 2012 |
McDonald JM, Cairns NJ, Taylor-Reinwald L, Holtzman D, Walsh DM. The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain. Brain Research. 1450: 138-47. PMID 22440675 DOI: 10.1016/J.Brainres.2012.02.041 |
0.447 |
|
| 2012 |
Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2: a006312. PMID 22393530 DOI: 10.1101/Cshperspect.A006312 |
0.456 |
|
| 2012 |
Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM. Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes. The Journal of Biological Chemistry. 287: 13959-71. PMID 22383525 DOI: 10.1074/Jbc.M111.288746 |
0.819 |
|
| 2012 |
Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology. 78: 709-19. PMID 22357717 DOI: 10.1212/Wnl.0B013E318248E568 |
0.433 |
|
| 2012 |
Selkoe D, Mandelkow E, Holtzman D. Deciphering Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2: a011460. PMID 22315723 DOI: 10.1101/Cshperspect.A011460 |
0.407 |
|
| 2012 |
Storandt M, Head D, Fagan AM, Holtzman DM, Morris JC. Toward a multifactorial model of Alzheimer disease. Neurobiology of Aging. 33: 2262-71. PMID 22261556 DOI: 10.1016/J.Neurobiolaging.2011.11.029 |
0.475 |
|
| 2012 |
Ances BM, Benzinger TL, Christensen JJ, Thomas J, Venkat R, Teshome M, Aldea P, Fagan AM, Holtzman DM, Morris JC, Clifford DB. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Archives of Neurology. 69: 72-7. PMID 22232345 DOI: 10.1001/Archneurol.2011.761 |
0.369 |
|
| 2012 |
Head D, Bugg JM, Goate AM, Fagan AM, Mintun MA, Benzinger T, Holtzman DM, Morris JC. Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. Archives of Neurology. 69: 636-43. PMID 22232206 DOI: 10.1001/Archneurol.2011.845 |
0.38 |
|
| 2012 |
Jiang M, Wang J, Fu J, Du L, Jeong H, West T, Xiang L, Peng Q, Hou Z, Cai H, Seredenina T, Arbez N, Zhu S, Sommers K, Qian J, ... ... Holtzman DM, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nature Medicine. 18: 153-8. PMID 22179319 DOI: 10.1038/Nm.2558 |
0.613 |
|
| 2012 |
Wang L, Fagan AM, Shah AR, Beg MF, Csernansky JG, Morris JC, Holtzman DM. Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type. Alzheimer Disease and Associated Disorders. 26: 314-21. PMID 22156755 DOI: 10.1097/Wad.0B013E31823C0Cf4 |
0.461 |
|
| 2012 |
Magnoni S, Esparza TJ, Conte V, Carbonara M, Carrabba G, Holtzman DM, Zipfel GJ, Stocchetti N, Brody DL. Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain : a Journal of Neurology. 135: 1268-80. PMID 22116192 DOI: 10.1093/Brain/Awr286 |
0.344 |
|
| 2012 |
Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim J, Yarasheski KE, Wang JX, Mawuenyega KG, Jiang H, Parsadanian M, Yoon H, Kasten T, Sigurdson WC, Xiong C, Goate A, ... Holtzman DM, et al. Correction: In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS Plos One. 7. DOI: 10.1371/Annotation/9Bd329B7-Cdea-45Ec-A4Aa-A173855Dc0B9 |
0.767 |
|
| 2012 |
Ju Y, Duntley S, Fagan A, Morris J, Holtzman D. Sleep Disruption and Risk of Preclinical Alzheimer Disease (P01.081) Neurology. 78: P01.081-P01.081. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P01.081 |
0.339 |
|
| 2012 |
Kim J, Eltorai A, Jiang H, Stewart F, Liao F, Holtzman DM. 36 Effect of Anti-ApoE antibodies on Aβ pathology and accumulation Neurobiology of Aging. 33: S16. DOI: 10.1016/J.Neurobiolaging.2012.01.054 |
0.386 |
|
| 2012 |
Brody D, Esparza T, Zhao H, Cirrito J, Cairns N, Bateman R, Holtzman D. P4-266: BETA-AMYLOID oligomerization in Alzheimer's DISEASE DEMENTIA versus high pathology controls Alzheimer's & Dementia. 8: S752-S752. DOI: 10.1016/J.Jalz.2013.08.047 |
0.744 |
|
| 2012 |
Roh JH, Stewart F, Holtzman D. Potential role of the sleep-wake cycle in the pathogenesis of Alzheimer's disease Alzheimers & Dementia. 8: 243. DOI: 10.1016/J.Jalz.2012.05.649 |
0.345 |
|
| 2012 |
Cruchaga C, Goate A, Thompson P, Kauwe J, Mayo K, Bertelsen S, Hinrichs T, Fagan A, Holtzman D. F2-02-04: Genome-wide association studies using cerebrospinal fluid biomarkers as an endophenotype for Alzheimer's disease Alzheimer's & Dementia. 8: P232-P233. DOI: 10.1016/J.Jalz.2012.05.615 |
0.354 |
|
| 2012 |
Sutphen CL, Shah AR, Amos M, Vlassenko AG, Benzinger TL, Holtzman DM, Morris JC, Fagan AM. O1-01-06: Longitudinal changes in cerebrospinal fluid biomarkers of Alzheimer's disease during middle-age in cognitively normal individuals with a positive family history Alzheimer's & Dementia. 8: P86-P86. DOI: 10.1016/J.Jalz.2012.05.207 |
0.345 |
|
| 2012 |
Bateman R, Benzinger T, Cairns N, Fagan A, Goate A, Marcus D, Storandt M, Xiong C, Buckles V, Holtzman D, Moulder K, Oliver A, Santacruz A, Fox N, Ghetti B, et al. Presymptomatic Alzheimer's disease in the Dominantly Inherited Alzheimer's Network (DIAN) Alzheimers & Dementia. 8: 4. DOI: 10.1016/J.Jalz.2012.05.015 |
0.574 |
|
| 2011 |
Holtzman DM, Goate A, Kelly J, Sperling R. Mapping the road forward in Alzheimer's disease. Science Translational Medicine. 3: 114ps48. PMID 22190237 DOI: 10.1126/Scitranslmed.3003529 |
0.462 |
|
| 2011 |
Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 18007-12. PMID 22159114 DOI: 10.1523/Jneurosci.3773-11.2011 |
0.855 |
|
| 2011 |
Legleiter J, Fryer JD, Holtzman DM, Kowalewski A. The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption. Acs Chemical Neuroscience. 2: 588-599. PMID 22125665 DOI: 10.1021/Cn2000475 |
0.433 |
|
| 2011 |
Holtzman DM. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiology of Aging. 32: S4-9. PMID 22078172 DOI: 10.1016/J.Neurobiolaging.2011.09.003 |
0.454 |
|
| 2011 |
Verghese PB, Sasaki Y, Yang D, Stewart F, Sabar F, Finn MB, Wroge CM, Mennerick S, Neil JJ, Milbrandt J, Holtzman DM. Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death. Proceedings of the National Academy of Sciences of the United States of America. 108: 19054-9. PMID 22058226 DOI: 10.1073/Pnas.1107325108 |
0.696 |
|
| 2011 |
Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ. Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 15861-9. PMID 22049429 DOI: 10.1523/Jneurosci.3272-11.2011 |
0.727 |
|
| 2011 |
Xiong C, Roe CM, Buckles V, Fagan A, Holtzman D, Balota D, Duchek J, Storandt M, Mintun M, Grant E, Snyder AZ, Head D, Benzinger TL, Mettenburg J, Csernansky J, et al. Role of family history for Alzheimer biomarker abnormalities in the adult children study. Archives of Neurology. 68: 1313-9. PMID 21987546 DOI: 10.1001/Archneurol.2011.208 |
0.431 |
|
| 2011 |
Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow EM, Diamond MI, Lee VM, Holtzman DM. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 13110-7. PMID 21917794 DOI: 10.1523/Jneurosci.2569-11.2011 |
0.704 |
|
| 2011 |
Roe CM, Fagan AM, Grant EA, Marcus DS, Benzinger TL, Mintun MA, Holtzman DM, Morris JC. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. Archives of Neurology. 68: 1145-51. PMID 21911695 DOI: 10.1001/archneurol.2011.192 |
0.351 |
|
| 2011 |
Cruchaga C, Nowotny P, Kauwe JS, Ridge PG, Mayo K, Bertelsen S, Hinrichs A, Fagan AM, Holtzman DM, Morris JC, Goate AM. Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Archives of Neurology. 68: 1013-9. PMID 21825236 DOI: 10.1001/Archneurol.2011.155 |
0.399 |
|
| 2011 |
Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Annals of Neurology. 70: 274-85. PMID 21823155 DOI: 10.1002/Ana.22448 |
0.463 |
|
| 2011 |
Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR. Opposing synaptic regulation of amyloid-β metabolism by NMDA receptors in vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 11328-37. PMID 21813692 DOI: 10.1523/Jneurosci.0607-11.2011 |
0.645 |
|
| 2011 |
Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, ... ... Holtzman DM, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 386-395.e6. PMID 21784349 DOI: 10.1016/J.Jalz.2011.05.2243 |
0.426 |
|
| 2011 |
Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Science Translational Medicine. 3: 89ra57. PMID 21715678 DOI: 10.1126/Scitranslmed.3002156 |
0.825 |
|
| 2011 |
Tran HT, LaFerla FM, Holtzman DM, Brody DL. Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 9513-25. PMID 21715616 DOI: 10.1523/Jneurosci.0858-11.2011 |
0.51 |
|
| 2011 |
Hata S, Fujishige S, Araki Y, Taniguchi M, Urakami K, Peskind E, Akatsu H, Araseki M, Yamamoto K, Martins RN, Maeda M, Nishimura M, Levey A, Chung KA, Montine T, ... ... Holtzman DM, et al. Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: evidence for γ-secretase dysfunction. Annals of Neurology. 69: 1026-31. PMID 21681798 DOI: 10.1002/Ana.22343 |
0.576 |
|
| 2011 |
Lim MM, Xu J, Holtzman DM, Mach RH. Sleep deprivation differentially affects dopamine receptor subtypes in mouse striatum. Neuroreport. 22: 489-93. PMID 21642879 DOI: 10.1097/Wnr.0B013E32834846A0 |
0.548 |
|
| 2011 |
Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JÅ, Holtzman DM, Heneka MT. Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 7049-59. PMID 21562267 DOI: 10.1523/Jneurosci.6546-10.2011 |
0.779 |
|
| 2011 |
Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Archives of Neurology. 68: 1137-44. PMID 21555603 DOI: 10.1001/Archneurol.2011.105 |
0.517 |
|
| 2011 |
Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nature Neuroscience. 14: 750-6. PMID 21532579 DOI: 10.1038/Nn.2801 |
0.839 |
|
| 2011 |
Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. Plos One. 6: e18850. PMID 21526197 DOI: 10.1371/Journal.Pone.0018850 |
0.813 |
|
| 2011 |
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 270-9. PMID 21514249 DOI: 10.1016/j.jalz.2011.03.008 |
0.307 |
|
| 2011 |
Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Science Translational Medicine. 3: 77sr1. PMID 21471435 DOI: 10.1126/Scitranslmed.3002369 |
0.433 |
|
| 2011 |
Lodygensky GA, West T, Moravec MD, Back SA, Dikranian K, Holtzman DM, Neil JJ. Diffusion characteristics associated with neuronal injury and glial activation following hypoxia-ischemia in the immature brain. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 66: 839-45. PMID 21394776 DOI: 10.1002/Mrm.22869 |
0.539 |
|
| 2011 |
Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. The Lancet. Neurology. 10: 241-52. PMID 21349439 DOI: 10.1016/S1474-4422(10)70325-2 |
0.826 |
|
| 2011 |
Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su'a M, Fagan AM, Holtzman DM, Morris JC, Goate AM. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. Plos One. 6: e15918. PMID 21347408 DOI: 10.1371/Journal.Pone.0015918 |
0.431 |
|
| 2011 |
Pasic MD, Diamandis EP, McLaurin J, Holtzman DM, Schmitt-Ulms G, Quirion R. Alzheimer disease: advances in pathogenesis, diagnosis, and therapy. Clinical Chemistry. 57: 664-9. PMID 21310870 DOI: 10.1373/Clinchem.2011.161828 |
0.473 |
|
| 2011 |
Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. Plos One. 6: e16032. PMID 21264269 DOI: 10.1371/Journal.Pone.0016032 |
0.825 |
|
| 2011 |
Roe CM, Fagan AM, Williams MM, Ghoshal N, Aeschleman M, Grant EA, Marcus DS, Mintun MA, Holtzman DM, Morris JC. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology. 76: 501-10. PMID 21228296 DOI: 10.1212/Wnl.0B013E31820Af900 |
0.335 |
|
| 2011 |
Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, Ghosh AK, Tang J. Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 25: 775-84. PMID 21059748 DOI: 10.1096/Fj.10-167213 |
0.695 |
|
| 2011 |
Elbert DL, Patterson BW, Ercole L, Ovod V, Kasten T, Mawuenyega K, Yarasheski K, Morris JC, Benzinger T, Holtzman DM, Bateman RJ. Reply to: Fractional synthesis and clearance rates for amyloid β Nature Medicine. 17: 1179-1180. DOI: 10.1038/Nm.2496 |
0.513 |
|
| 2011 |
Kauwe J, Cruchaga C, McKean D, Bailey M, Patty D, Mayo K, Bertelsen S, Hinrichs A, Disease Genetics Consortium TA, Disease Neuroimaging Initiative TA, Fagan A, Holtzman D, Goate A. P4-453: Genome-wide association analysis using cerebrospinal fluid Abeta42 levels as an endophenotype for Alzheimer's disease Alzheimer's & Dementia. 7: e69-e70. DOI: 10.1016/J.Jalz.2011.09.148 |
0.415 |
|
| 2011 |
Bailey M, Kauwe J, Cruchaga C, McKean D, Mayo K, Bertelsen S, Hinrichs T, Fagan A, Holtzman D, Goate A. P2-018: Association study of recently reported AD risk variants with cerebrospinal fluid AD biomarker levels Alzheimer's & Dementia. 7: S313-S313. DOI: 10.1016/J.Jalz.2011.05.908 |
0.426 |
|
| 2011 |
Head D, Bugg J, Goate A, Fagan A, Mintun M, Benzinger T, Holtzman D, Morris J. P1-377: Interactive effects of a sedentary lifestyle and the APOE e4 allele on amyloid deposition Alzheimer's & Dementia. 7: S233-S233. DOI: 10.1016/J.Jalz.2011.05.658 |
0.374 |
|
| 2011 |
Cruchaga C, Nowotny P, Kauwe J, Mayo K, Bertelsen S, Hinrichs T, Fagan A, Holtzman D, Morris J, Goate A. P1-224: APOE Genotype is Associated with Cerebrospinal Fluid and Plasma APOE Levels But Not with APOE Expression Levels Alzheimer's & Dementia. 7: S182-S183. DOI: 10.1016/J.Jalz.2011.05.504 |
0.329 |
|
| 2011 |
Cruchaga C, Kauwe J, Mayo K, Bertelsen S, Hinrichs T, Peskind E, Li G, Leverenz J, Galasko D, Fagan A, Holtzman D, Goate A. Genome-Wide Association Analyses Using Cerebrospinal Fluid Tau and Phospho-Tau Levels As An Endophenotype for Alzheimer’s Disease Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.503 |
0.385 |
|
| 2011 |
Benitez B, Cruchaga C, Kauwe J, Mayo K, Bertelsen S, Hinrichs A, Fagan A, Holtzman D, Goate A. Rare Genetic Variants in APP, PSEN1, PSEN2, GRN, APOE and MAPT Associated with CSF Aß and tau/ptau181 Levels in Patients with Late-Onset Alzheimer’s Disease Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.492 |
0.416 |
|
| 2011 |
Snider BJ, Holtzman D, Fagan A, Ghoshal N, Morris J. P1-114: Diagnostic utility of CSF biomarkers in an Alzheimer's clinic Alzheimer's & Dementia. 7: S146-S146. DOI: 10.1016/J.Jalz.2011.05.393 |
0.37 |
|
| 2011 |
Hu WT, Holtzman D, Clark C, Grossman M, Karlawish J, Fagan A, Lee V, Swenson F, Craig-Schapiro R, Perrin RJ, Soares H, Trojanowski J, Xiong C, Morris J, Shaw L, et al. P1-089: Plasma multianalyte profiling of mild cognitive impairment and Alzheimer's disease in two academic centers and the Alzheimer's Disease Neuroimaging Initiative Alzheimer's & Dementia. 7: S138-S138. DOI: 10.1016/J.Jalz.2011.05.368 |
0.81 |
|
| 2011 |
Holtzman D, Hyman B, Lee V, Spires-Jones T, Koffie R, Hashimoto T, Joyner D, Hou S, Kopeikina K, Frosch M. O1-05-01: APOE4 plays a role in Abeta-mediated synapse loss in Alzheimer's disease Alzheimer's & Dementia. 7: S103-S104. DOI: 10.1016/J.Jalz.2011.05.256 |
0.421 |
|
| 2011 |
Goate A, Holtzman D, Morris J, Cruchaga C, Nowotny P, Kauwe J, Fagan A, Mayo K, Bertelsen S, Hinrichs T. Association and expression analyses with SNPs in TOMM40 in Alzheimer's disease Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.227 |
0.37 |
|
| 2011 |
Fagan A, Xiong C, Bateman R, Goate A, Holtzman D, Ghetti B, Martins R, Masters C, Mayeux R, Ringman J, Rossor M, Salloway S, Schofield P, Sperling R, Morris J. Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer’s Disease Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.1960 |
0.491 |
|
| 2011 |
Castellano J, Verghese P, Stewart F, DeMattos R, Holtzman D. P2-221: Synthetic human apoE particles differentially regulate brain interstitial amyloid-beta levels Alzheimer's & Dementia. 7: S383-S383. DOI: 10.1016/J.Jalz.2011.05.1103 |
0.78 |
|
| 2011 |
Basak JM, Holtzman DM. APP-based transgenic models: The PDAPP model Neuromethods. 48: 371-385. DOI: 10.1007/978-1-60761-898-0_18 |
0.739 |
|
| 2010 |
Kim J, Holtzman DM. Medicine. Prion-like behavior of amyloid-beta. Science (New York, N.Y.). 330: 918-9. PMID 21071652 DOI: 10.1126/Science.1198314 |
0.671 |
|
| 2010 |
Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, ... ... Holtzman DM, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biological Psychiatry. 68: 903-12. PMID 21035623 DOI: 10.1016/J.Biopsych.2010.08.025 |
0.84 |
|
| 2010 |
Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MM, Williams J, Lovestone S, Peskind ER, Li G, ... ... Holtzman DM, et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. Plos Genetics. 6: e1001101. PMID 20862329 DOI: 10.1371/Journal.Pgen.1001101 |
0.448 |
|
| 2010 |
Galvin JE, Fagan AM, Holtzman DM, Mintun MA, Morris JC. Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain : a Journal of Neurology. 133: 3290-300. PMID 20823087 DOI: 10.1093/Brain/Awq204 |
0.463 |
|
| 2010 |
Liang KY, Mintun MA, Fagan AM, Goate AM, Bugg JM, Holtzman DM, Morris JC, Head D. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Annals of Neurology. 68: 311-8. PMID 20818789 DOI: 10.1002/Ana.22096 |
0.387 |
|
| 2010 |
Schwetye KE, Cirrito JR, Esparza TJ, Mac Donald CL, Holtzman DM, Brody DL. Traumatic brain injury reduces soluble extracellular amyloid-β in mice: a methodologically novel combined microdialysis-controlled cortical impact study. Neurobiology of Disease. 40: 555-64. PMID 20682338 DOI: 10.1016/J.Nbd.2010.06.018 |
0.645 |
|
| 2010 |
Satoh A, Brace CS, Ben-Josef G, West T, Wozniak DF, Holtzman DM, Herzog ED, Imai S. SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 10220-32. PMID 20668205 DOI: 10.1523/Jneurosci.1385-10.2010 |
0.736 |
|
| 2010 |
Kauwe JS, Cruchaga C, Bertelsen S, Mayo K, Latu W, Nowotny P, Hinrichs AL, Fagan AM, Holtzman DM, Goate AM. Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. Journal of Alzheimer's Disease : Jad. 21: 833-42. PMID 20634593 DOI: 10.3233/Jad-2010-091711 |
0.404 |
|
| 2010 |
Ances BM, Christensen JJ, Teshome M, Taylor J, Xiong C, Aldea P, Fagan AM, Holtzman DM, Morris JC, Mintun MA, Clifford DB. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology. 75: 111-5. PMID 20534887 DOI: 10.1212/Wnl.0B013E3181E7B66E |
0.366 |
|
| 2010 |
Tarawneh R, Holtzman DM. Biomarkers in translational research of Alzheimer's disease. Neuropharmacology. 59: 310-22. PMID 20394760 DOI: 10.1016/J.Neuropharm.2010.04.006 |
0.531 |
|
| 2010 |
Dietrich HH, Xiang C, Han BH, Zipfel GJ, Holtzman DM. Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Molecular Neurodegeneration. 5: 15. PMID 20388225 DOI: 10.1186/1750-1326-5-15 |
0.414 |
|
| 2010 |
Goate A, Holtzman DM. Biomarkers will revolutionize the way we diagnose and treat Alzheimer's disease. Biomarkers in Medicine. 4: 1-2. PMID 20387300 DOI: 10.2217/Bmm.10.3 |
0.416 |
|
| 2010 |
Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomarkers in Medicine. 4: 51-63. PMID 20361010 DOI: 10.2217/Bmm.09.83 |
0.416 |
|
| 2010 |
Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Annals of Neurology. 67: 122-31. PMID 20186853 DOI: 10.1002/Ana.21843 |
0.461 |
|
| 2010 |
Zeng C, Pan F, Jones LA, Lim MM, Griffin EA, Sheline YI, Mintun MA, Holtzman DM, Mach RH. Evaluation of 5-ethynyl-2'-deoxyuridine staining as a sensitive and reliable method for studying cell proliferation in the adult nervous system. Brain Research. 1319: 21-32. PMID 20064490 DOI: 10.1016/J.Brainres.2009.12.092 |
0.541 |
|
| 2010 |
Zeng LH, Bero AW, Zhang B, Holtzman DM, Wong M. Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex. Neurobiology of Disease. 37: 764-71. PMID 20045054 DOI: 10.1016/J.Nbd.2009.12.020 |
0.777 |
|
| 2010 |
Lodygensky GA, West T, Stump M, Holtzman DM, Inder TE, Neil JJ. In vivo MRI analysis of an inflammatory injury in the developing brain. Brain, Behavior, and Immunity. 24: 759-67. PMID 19945527 DOI: 10.1016/J.Bbi.2009.11.005 |
0.529 |
|
| 2010 |
Hinrichs AL, Mintun MA, Head D, Fagan AM, Holtzman DM, Morris JC, Goate AM. Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease. Biological Psychiatry. 67: 581-3. PMID 19892322 DOI: 10.1016/J.Biopsych.2009.09.012 |
0.436 |
|
| 2010 |
Cheng H, Zhou Y, Holtzman DM, Han X. Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease. Neurobiology of Aging. 31: 1188-96. PMID 18762354 DOI: 10.1016/J.Neurobiolaging.2008.07.020 |
0.525 |
|
| 2010 |
Snider BJ, Pizzie RG, Roe CM, Grant EA, Fagan AM, Holtzman DM, Morris JC. P4-149: Accuracy of Clinical Diagnosis of Dementia of the Alzheimer Type: Impact of Longitudinal Follow-up and Inclusion of CSF Biomarkers Alzheimer's & Dementia. 6: e67-e67. DOI: 10.1016/J.Jalz.2010.08.208 |
0.378 |
|
| 2010 |
Tarawneh R, Ohlendorf MF, Macy EM, McQuillan J, Head D, Cairns NJ, Fagan AM, Mintun MA, Ladenson JH, Lee J, Morris JC, Holtzman DM. P4-060: The Novel Neuronal Injury Marker, Visinin-like Protein-1 (VILIP-1), as a Diagnostic and Prognostic Marker in Alzheimer's Disease Alzheimer's & Dementia. 6: e38-e39. DOI: 10.1016/J.Jalz.2010.08.120 |
0.355 |
|
| 2010 |
Brautigam H, Klingstedt T, Prokop S, Holtzman DM, Heppner FL, Haroutunian V, Dickstein DL, Hof PR, Nilsson PR, Gandy S. O4-08-06: New Conformation-Sensing Imaging Compounds Distinguish Protein Deposits In Apoe
ε3/ε3 Alzheimer's Patients From that in Apoe
ε4/ε4 Alzheimer's Patients Alzheimer's & Dementia. 6: e19-e20. DOI: 10.1016/J.Jalz.2010.08.059 |
0.394 |
|
| 2010 |
Karch CM, Jeng A, Cruchaga C, Kauwe JS, Renaud N, Fagan AM, Holtzman DM, Morris JC, Goate AM. P1-090: The effects of Alzheimer's disease associated transferrin variants on APP metabolism Alzheimer's & Dementia. 6: S200-S200. DOI: 10.1016/J.Jalz.2010.05.638 |
0.415 |
|
| 2010 |
Cruchaga C, Kauwe JS, Mayo K, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MJ, Williams J, Lovestone S, Morris JC, Fagan AM, Holtzman DM, et al. SNPs associated with CSF tau levels modify rate of progression in Alzheimer's disease Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.612 |
0.32 |
|
| 2010 |
Bero AW, Stewart FR, Parsadanian M, Holtzman DM. O4-02-06: Regional cerebral glucose metabolism is associated with interstitial fluid Aβ concentration and plaque deposition in Tg2576 mice Alzheimer's & Dementia. 6: S154-S154. DOI: 10.1016/J.Jalz.2010.05.478 |
0.81 |
|
| 2010 |
Castellano JM, Stewart FR, May PC, DeMattos RB, Paul SM, Holtzman DM. O4-02-03: Soluble Aβ clearance from the brain interstitial fluid of PDAPP mice is human apoE isoform-dependent Alzheimer's & Dementia. 6: S153-S153. DOI: 10.1016/J.Jalz.2010.05.475 |
0.658 |
|
| 2010 |
Kauwe JSK, Cruchaga C, Bertelsen S, Mayo K, Latu W, Nowotny P, Hinrichs AL, Fagan AM, Holtzman DM, Goate AM. Validating predicted biological effects of Alzheimer's disease associated SNPs using cerebrospinal fluid biomarker levels Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.348 |
0.371 |
|
| 2010 |
Galvin JE, Fagan AM, Holtzman DM, Storandt M, Mintun MA, Morris JC. P3-223: Correlation of the AD8, an informant-based dementia screening tool, with amyloid imaging and CSF biomarkers of Alzheimer disease Alzheimer's & Dementia. 6: S516-S516. DOI: 10.1016/j.jalz.2010.05.1722 |
0.346 |
|
| 2010 |
Craig-Schapiro R, Perrin RJ, Roe CM, Grant EA, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, ... ... Holtzman DM, et al. P3-190: A novel diagnostic and prognostic fluid biomarker for early Alzheimer's disease: YKL-40 Alzheimer's & Dementia. 6: S506-S506. DOI: 10.1016/J.Jalz.2010.05.1688 |
0.806 |
|
| 2010 |
Perrin RJ, Craig-Schapiro R, Malone JP, Roe CM, Grant EA, Shah AR, Gilmore P, Davis AE, Peskind ER, Li G, Galasko DR, Quinn JF, Kaye JA, Clark CM, Morris JC, ... Holtzman DM, et al. P3-172: Identification and validation of novel cerebrospinal fluid protein biomarkers for early Alzheimer's disease using proteomics and ELISA: a multi-institutional collaborative study Alzheimer's & Dementia. 6: S500-S500. DOI: 10.1016/J.Jalz.2010.05.1670 |
0.775 |
|
| 2010 |
Hata S, Urakami K, Fagan A, Peskind E, Akatsu H, Maeda M, Levey A, Chung KA, Montine T, Leverenz J, Goate A, Bateman R, Holtzman DM, Gandy S, Suzuki T. P3-171: Gamma-secretase dysfunction in sporadic Alzhemer's disease suggested by p3-Alc peptide, metabolic product of Alcadein Alzheimer's & Dementia. 6: S499-S500. DOI: 10.1016/J.Jalz.2010.05.1669 |
0.495 |
|
| 2010 |
Galvin JE, Fagan AM, Holtzman DM, Storandt M, Mintun MA, Morris JC. IC-P-007: Correlation of the AD8: an Informant-Based Dementia Screening Tool with Amyloid Imaging and CSF Biomarkers of Alzheimer Disease Alzheimer's & Dementia. 6: S8-S9. DOI: 10.1016/J.Jalz.2010.05.022 |
0.42 |
|
| 2010 |
Holtzman D. Diagnostic markers: Detection of preclinical pathology, prognostic capabilities, and dynamic metabolism of Abeta and tau Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.003 |
0.376 |
|
| 2009 |
Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. Embo Molecular Medicine. 1: 371-80. PMID 20049742 DOI: 10.1002/Emmm.200900048 |
0.528 |
|
| 2009 |
Holtzman DM. A surrogate marker for Abeta42 production in the CNS. Embo Molecular Medicine. 1: 195-7. PMID 20049720 DOI: 10.1002/Emmm.200900030 |
0.513 |
|
| 2009 |
Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL, Westaway D, Fraser P, Hyslop PS, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S. Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Molecular Neurodegeneration. 4: 51. PMID 20017949 DOI: 10.1186/1750-1326-4-51 |
0.704 |
|
| 2009 |
Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Archives of Neurology. 66: 1557-62. PMID 20008664 DOI: 10.1001/Archneurol.2009.279 |
0.462 |
|
| 2009 |
Holtzman DM. Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization. Archives of Neurology. 66: 1552-3. PMID 20008662 DOI: 10.1001/Archneurol.2009.270 |
0.485 |
|
| 2009 |
Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Archives of Neurology. 66: 1469-75. PMID 20008650 DOI: 10.1001/Archneurol.2009.269 |
0.412 |
|
| 2009 |
Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 64: 632-44. PMID 20005821 DOI: 10.1016/J.Neuron.2009.11.013 |
0.837 |
|
| 2009 |
Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, Kauwe JS. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology. 73: 1982-7. PMID 19907013 DOI: 10.1212/Wnl.0B013E3181C5B445 |
0.385 |
|
| 2009 |
Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 461: 916-22. PMID 19829371 DOI: 10.1038/Nature08538 |
0.665 |
|
| 2009 |
Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (New York, N.Y.). 326: 1005-7. PMID 19779148 DOI: 10.1126/Science.1180962 |
0.803 |
|
| 2009 |
Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 10706-14. PMID 19710322 DOI: 10.1523/Jneurosci.2637-09.2009 |
0.834 |
|
| 2009 |
Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 63: 287-303. PMID 19679070 DOI: 10.1016/J.Neuron.2009.06.026 |
0.847 |
|
| 2009 |
Aslund A, Sigurdson CJ, Klingstedt T, Grathwohl S, Bolmont T, Dickstein DL, Glimsdal E, Prokop S, Lindgren M, Konradsson P, Holtzman DM, Hof PR, Heppner FL, Gandy S, Jucker M, et al. Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. Acs Chemical Biology. 4: 673-84. PMID 19624097 DOI: 10.1021/Cb900112V |
0.455 |
|
| 2009 |
Cao C, Cirrito JR, Lin X, Wang L, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. Journal of Alzheimer's Disease : Jad. 17: 681-97. PMID 19581723 DOI: 10.3233/Jad-2009-1071 |
0.713 |
|
| 2009 |
Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 106: 12145-50. PMID 19581601 DOI: 10.1073/Pnas.0904866106 |
0.574 |
|
| 2009 |
West T, Stump M, Lodygensky G, Neil JJ, Deshmukh M, Holtzman DM. Lack of X-linked inhibitor of apoptosis protein leads to increased apoptosis and tissue loss following neonatal brain injury. Asn Neuro. 1. PMID 19570023 DOI: 10.1042/An20090005 |
0.555 |
|
| 2009 |
Yuede CM, Zimmerman SD, Dong H, Kling MJ, Bero AW, Holtzman DM, Timson BF, Csernansky JG. Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer's disease. Neurobiology of Disease. 35: 426-32. PMID 19524672 DOI: 10.1016/J.Nbd.2009.06.002 |
0.82 |
|
| 2009 |
Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Archives of Neurology. 66: 638-45. PMID 19433664 DOI: 10.1001/Archneurol.2009.55 |
0.464 |
|
| 2009 |
Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Annals of Neurology. 66: 48-54. PMID 19360898 DOI: 10.1002/Ana.21623 |
0.579 |
|
| 2009 |
Tarawneh R, Holtzman DM. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. Cns & Neurological Disorders Drug Targets. 8: 144-59. PMID 19355934 DOI: 10.2174/187152709787847324 |
0.476 |
|
| 2009 |
Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 4252-62. PMID 19339619 DOI: 10.1523/Jneurosci.5572-08.2009 |
0.428 |
|
| 2009 |
Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Annals of Neurology. 65: 176-83. PMID 19260027 DOI: 10.1002/Ana.21559 |
0.522 |
|
| 2009 |
Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer's disease. Neurobiology of Disease. 35: 128-40. PMID 19010417 DOI: 10.1016/J.Nbd.2008.10.003 |
0.779 |
|
| 2009 |
Kauwe JS, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, Goate AM. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics. 10: 13-7. PMID 18813964 DOI: 10.1007/S10048-008-0150-4 |
0.443 |
|
| 2009 |
Gandy S, Cirrito J, Steele J, Kim SH, Thinakaran G, Westaway D, Fraser P, St George Hyslop P, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM. S4-04-06: Dimebon®: A Clinically Promising Drug for Alzheimer's Disease, Regulates Amyloid-Beta Metabolism in Cultured Cells, In Isolated Nerve Terminals, and In the Interstitial Fluid of the Living Rodent Brain Alzheimer's & Dementia. 5: e5-e5. DOI: 10.1016/J.Jalz.2009.07.133 |
0.665 |
|
| 2009 |
Kraft AW, Hu X, Yan P, Xiao Q, Holmes BB, Wilhelmsson U, Cirrito JR, Holtzman DM, Pekny M, Lee J. Activated astrocytes suppress amyloid plaque pathogenesis in APP/PS1 mice Alzheimers & Dementia. 5: 154. DOI: 10.1016/J.Jalz.2009.05.532 |
0.693 |
|
| Show low-probability matches. |
